

RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD THEREFOR, RECOMBINANT PLASMID, AND USE THEREOF

Technical Field

5 **[0001]** The present application in general relates to the field of biotechnologies, in particular to a recombinant Newcastle disease virus and a preparation method therefor, a recombinant plasmid, and use thereof.

Background

10 **[0002]** Major means for treating cancers include surgeries, radiotherapies, chemotherapies, immunotherapies, monoclonal antibody therapies, and viral vaccines.

15 **[0003]** Malignant tumours are one of the major diseases endangering human's health. According to the data in 2015 Global Cancer Statistics, there were about 14.1 million new cancer cases and up to 8.2 million cancer deaths across the world in 2015. It is predicted that by 2025, the number of new cancer cases across the world every year will reach up to 24.49 million. For a long time, the methods adopted by people to treat cancers mainly include traditional surgical resections, radiotherapies, and chemotherapies. These methods can control the development of tumours to some extent, but showing limited efficacy for patients with advanced tumour spread, and at the same time, causing severe trauma to the normal cells of a human body. Therefore, there is an urgent need of a new method for treating a malignant tumour. An oncolytic virus therapy is a novel tumour treatment method by which a tumour is killed by selectively infecting tumour cells with viruses. As an important part of tumour immunity, it has a great advantage as compared with other tumour immunotherapies. The oncolytic virus therapy has undergone three stages of development, and has achieved great results. At present, the anti-tumour effect can be enhanced by carrying exogenous genes, among which T-vec carrying GM-CSF exhibits a good efficacy and was approved by the US FDA in 2015 for the local treatment of an unresectable melanoma that recurred for the first time. In December of the same year, T-vec was

20

25

further approved by the European Union, indicating a great development potential of oncolytic viruses.

[0004] In 1950s, it was found that Newcastle disease viruses (NDV) were capable of inhibiting the metastasis of gastric cancer. Therefore, NDV can be used as an emerging tumour bio-therapeutic factor, and its application to tumour treatment has been studied deeper and deeper due to its high targeting property and the maturity of molecular biotechnologies. As a single negative-stranded RNA virus, NDV encodes six types of structural proteins (L, NP, P, HN, F, and M).

[0005] Compared with other oncolytic viruses, the Newcastle disease virus has a natural targeting property against tumour cells, and broad-spectrum anti-tumour properties, showing greater advantages in the anti-tumour aspect. However, how to improve its oncolytic effect and to ensure its safety is still a huge challenge for us to be confronted with.

Summary

[0006] An object of the present application is to provide a recombinant Newcastle disease virus and a preparation method therefor, a recombinant plasmid, and use thereof.

[0007] The present application provides a recombinant Newcastle disease virus obtained by replacing an F protein of a Newcastle disease virus Losata with an F protein of a Newcastle disease virus mesogenic strain.

[0008] Optionally, according to the recombinant Newcastle disease virus mentioned above, a coding DNA of an F protein of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1 at positions 7274-8935 from a 5'-terminus.

[0009] Optionally, according to the recombinant Newcastle disease virus mentioned above, the recombinant Newcastle disease virus is obtained by replacing

an F gene in a genome of the Newcastle disease virus Losata with an F gene of the Newcastle disease virus mesogenic strain. Preferably, a DNA corresponding to the F gene of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1 at the positions 7274-8935 from the 5'-terminus. More preferably, a DNA corresponding to a genome of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1.

[0010] Optionally, according to the recombinant Newcastle disease virus mentioned above, a DNA corresponding to a genome of the recombinant Newcastle disease virus further comprises an exogenous gene, which is selected from one or more of a group consisting of DR5, TRAIL, hIL2, P53, PD1, CD, and mIL12.

[0011] Preferably, the exogenous gene is DR5, TRAIL, hIL2, P53, PD1, CD, or mIL12.

[0012] Preferably, the exogenous gene is mIL12-hIL2, P53-hIL2, PD1-hIL2, or DR5-TRAIL.

[0013] Preferably, the DR5 is as set forth in SEQ ID NO: 2, the TRAIL is as set forth in SEQ ID NO: 3, the hIL2 is as set forth in SEQ ID NO: 4, the P53 is as set forth in SEQ ID NO: 5, the PD1 is as set forth in SEQ ID NO: 6, the CD is as set forth in SEQ ID NO: 7, and the mIL12 is as set forth in SEQ ID NO: 8.

[0014] Preferably, the exogenous gene is located between a P gene and an M gene of the recombinant Newcastle disease virus.

[0015] The present application further provides a recombinant plasmid obtained by replacing an F gene in a pBrLosata plasmid, wherein the F gene of the recombinant plasmid is as set forth in SEQ ID NO: 1 at positions 7274-8935 from a 5'-terminus.

[0016] Optionally, according to the recombinant plasmid mentioned above,

the recombinant plasmid is a DNA molecule plasmid as set forth in SEQ ID NO: 1.

[0017] Optionally, according to the recombinant plasmid mentioned above, the recombinant plasmid further comprises an exogenous gene, which is selected from one or more of a group consisting of DR5, TRAIL, hIL2, P53, PD1, CD, and mIL12.

5 **[0018]** Preferably, the exogenous gene is DR5, TRAIL, hIL2, P53, PD1, CD, or mIL12.

[0019] Preferably, the exogenous gene is mIL12-hIL2, P53-hIL2, PD1-hIL2, or DR5-TRAIL.

10 **[0020]** Preferably, the DR5 is as set forth in SEQ ID NO: 2, the TRAIL is as set forth in SEQ ID NO: 3, the hIL2 is as set forth in SEQ ID NO: 4, the P53 is as set forth in SEQ ID NO: 5, the PD1 is as set forth in SEQ ID NO: 6, the CD is as set forth in SEQ ID NO: 7, and the mIL12 is as set forth in SEQ ID NO: 8.

[0021] Preferably, the exogenous gene is located between a P gene and an M gene of a genome of the recombinant Newcastle disease virus.

15 **[0022]** The present application further provides a preparation method for a recombinant Newcastle disease virus, comprising transfecting the recombinant plasmid mentioned above to cells or cell line for culturing to obtain the recombinant Newcastle disease virus.

20 **[0023]** Optionally, according to the preparation method mentioned above, the recombinant plasmid and a helper plasmid are co-transfected to cells or cell line for culturing. The cell is a mammalian cell. The helper plasmid is, for example, a pBL-N plasmid, a pBL-P plasmid, or a pBL-L plasmid.

[0024] The present application further provides use of the recombinant Newcastle disease virus mentioned above or the recombinant plasmid mentioned

above in preparation of a drug. The drug has the following function(s) of (a) and/or (b) and/or (c): (a) treating a tumour; (b) inhibiting tumour cell proliferation; and (c) killing a tumour cell.

5 **[0025]** The present application further provides a drug, comprising the recombinant Newcastle disease virus mentioned above, and /or the recombinant plasmid mentioned above. The drug has the following function(s) of (a) and/or (b) and/or (c): (a) treating a tumour; (b) inhibiting tumour cell proliferation; and (c) killing tumour cells.

10 **[0026]** Optionally, the tumour is selected from one or more of a group consisting of a liver cancer, a breast cancer, a non-small cell lung cancer, a melanoma, a neuroblastoma, a lung cancer, a pancreatic cancer, a thyroid cancer, a kidney cancer, a glioma, a myosarcoma, an esophageal cancer, a uterine cancer, a breast cancer, and a colorectal cancer.

15 **[0027]** Optionally, the tumour cell is selected from one or more of a group consisting of a liver cancer cell, a breast cancer cell, a non-small cell lung cancer cell, a melanoma cell, a neuroblastoma cell, a lung cancer cell, a pancreatic cancer cell, a thyroid cancer cell, a kidney cancer cell, a glioma cell, a myosarcoma cell, an esophageal cancer cell, an uterine cancer cell, a breast cancer cell, and a colorectal cancer cell.

20 **[0028]** In the present application, virus strains having a stronger effect of promoting cell fusion are screened out; the structural protein genes of the strains are acquired; structural protein genes of Losata are replaced by means of a reverse genetic manipulation technique and a molecular cloning technique; and exogenous genes are further inserted to successfully construct and rescue recombinant chimeric viruses.
25 The recombinant chimeric viruses are continuously passaged in chicken embryos for 10 generations. The results of a proliferation stability experiment have demonstrated that the recombinant Newcastle disease virus could proliferate continuously and

stably in the chicken embryos, and the effects of the recombinant chimeric virus on killing tumour cells are systematically compared.

[0029] The recombinant chimeric virus according to the present application has good safety and is capable of effectively inhibiting tumour cells, promoting tumour cell apoptosis, and effectively treating a tumour.

Brief Description of the Drawings

[0030] FIG. 1 shows the results of a virus strain screening test according to Example 1;

[0031] FIG. 2 shows the results of an exogenous gene expression position determination test according to Example 2;

[0032] FIG. 3A to FIG. 3E show the killing effects of a recombinant chimeric virus against tumour cells as detected in a cell fusion experiment according to Example 4;

[0033] FIG. 4 shows the killing effect of a recombinant chimeric virus against HepG-2 cells as detected by an MTT method according to Example 5;

[0034] FIG. 5 shows the killing effect of the recombinant chimeric virus against Caki-1 cells as detected by the MTT method according to Example 5;

[0035] FIG. 6 shows the killing effect of the recombinant chimeric virus against A549 cells as detected by the MTT method according to Example 5;

[0036] FIG. 7 shows the killing effect of the recombinant chimeric virus against SK-MEL-5 cells as detected by the MTT method according to Example 5;

[0037] FIG. 8 shows the killing effect of the recombinant chimeric virus against LN229 cells as detected by an MTT method according to Example 5;

[0038] FIG. 9 shows the killing effect of the recombinant chimeric virus against liver cancer cells as detected by an Annexin V/PI method according to Example 5;

[0039] FIG. 10 shows the statistics of tumour volume after H22 tumour-bearing mice are treated with a recombinant chimeric virus according to

Example 6;

[0040] FIG. 11 shows the statistics of tumour weight after the H22 tumour-bearing mice are treated with the recombinant chimeric virus according to Example 6;

5 [0041] FIG. 12 shows the statistics of survival rate of the H22 tumour-bearing mice treated with the recombinant chimeric virus according to Example 6; and

[0042] FIG. 13 shows the pathological observations of tumour tissues after the H22 tumour-bearing mice are treated with the recombinant chimeric virus
10 according to Example 6.

Detailed Description of Embodiments

[0043] Specific embodiments of the present application will be illustrated
15 below in further detail in combination with accompanying drawings and examples for a better understanding of the solutions of the present application as well as the advantages thereof in various aspects. Nevertheless, the specific embodiments and examples described below are merely for an illustrative purpose, and are not intended to limit the present application.

20 [0044] The experimental methods in the examples below are conventional methods, unless otherwise stated. Test materials used in the examples below are purchased from common biochemical reagent stores, unless otherwise stated. For quantitative tests in the examples below, three repeated experiments are set up, and the results are averaged. Unless otherwise specified in the following examples, the
25 technical means used in these examples are conventional means well-known to a person skilled in the art or common commercially-available instruments and reagents. References can be made to *Molecular Cloning: A Laboratory Manual* (Third Edition) (Science Press), *Microbiological Experiments* (Fourth Edition) (Higher Education Press), and the manufacturer's instructions for use for the corresponding instruments

and reagents, etc.

[0045] A reference mentioning “pBrLosata plasmid” is “Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumour Effect” (Ziye Pan, PLOS ONE.; Harbin Boxiang Medical Technology Development Co., Ltd.).

[0046] A reference mentioning “pBL-N plasmid”, “pBL-P plasmid”, and “pBL-L plasmid” is “Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy” (Fuliang Bai, Immunology letters; Harbin Boxiang Medical Technology Development Co., Ltd.).

[0047] The pBrLosata plasmid contains the NP, P, M, F, HN, and L genes of the Newcastle disease virus, with PmeI and SacII digestion recognition sites between the P gene and the M gene. The pBrLosata, pBL-N, pBL-P, and pBL-L plasmids are co-transfected to mammalian cells and cultured (with the pBL-N, pBL-P, and pBL-L plasmids as helpers, and the pBrLosata plasmid providing a virus whole-genome) to obtain a virus strain Losata.

[0048] The exogenous genes involved herein include a death receptor gene *DR5*, a tumour necrosis factor-related apoptosis-inducing ligand gene *TRAIL*, a human interleukin gene *2hIL2*, a cancer suppressor gene *P53*, a programmed death receptor 1 gene *PD1*, a suicide gene *CD*, and a murine interleukin gene *12mIL12*.

[0049] pMD19-T: purchased from TaKaRa Engineering (Dalian) Co., Ltd. (Dalian TaKaRa Bio Inc.).

[0050] BHK-21 cells (baby hamster kidney cells): purchased from ATCC.

[0051] Liver cancer cells HepG2, kidney cancer cells Caki-1, non-small cells lung cancer cells A549, neuroblastoma cells LN229, melanoma cells SK-MEL5, liver cancer cells HCCLM3, melanoma cells SK-MEL2, pancreatic cancer cells

ASPC-1, thyroid cancer cells FTC133, kidney cancer cells 786-O, neuroblastoma cells U87-MG, myosarcoma cells HT1080, esophageal cancer cells KYSE-150, uterine cancer cells Hela, breast cancer cells MCF7, and colorectal cancer cells HCT116 were purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

[0052] High-glucose DMEM medium, trypsin, new born calf serum (NBCS), and fetal bovine serum (FBS): purchased from GIBCO.

[0053] SPF chicken embryo: purchased from Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

[0054] Balb/c mice (Kunming mice): purchased from Vital River Laboratories, Beijing.

[0055] Example 1: Virus strain screening

[0056] Chicken embryo fibroblasts in a logarithmic growth phase were digested with trypsin and collected, and then seeded into a 6-well plate. Three virulent Newcastle disease virus strains F48E9, Turkey/US(ND)/43084/92 (TkND) and Game fowl/US(CA)/211472/02 (CA02) and one mesogenic strain Anhinga (the strains were donated by Southeast Poultry Research Laboratory and stored in our laboratory, and a reference mentioning the virus strains included “Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone”. Virus Research, Volume 129, Issue 2, November 2007, Pages 182-190) infected cells at 0.1 MOI respectively, and a control group was a virus-free SPF chicken embryo allantoic fluid. After 24 h, the 6-well plate were taken out and observed under an inverted fluorescence microscope for a cell fusion effect. By analysing a syncytial formation capability, virus strains having strong fusion capability and weak virulence were screened out for subsequent experiments. The results were shown in FIG. 1. Among

the four virus strains, F48E9 showed the strongest fusion-promoting capability, and the strain Anhinga shows a stronger fusion-promoting capability and the weakest virulence.

[0057] Example 2: Preparation of recombinant chimeric virus

5 **[0058]** I. Construction of recombinant plasmid (taking F gene replacement as an example)

[0059] 1. The virus strain Anhinga with a stronger fusion-promoting effect and weaker virulence was screened out, and the sequence of its F gene was acquired from NCBI (GenBank: AAS67135.1), and overlap PCR primers were designed.

10 **[0060]** 2. Taking a pAnh plasmid (the involved reference was “Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone”) as a template, an F gene fragment was amplified by PCR by using F gene specific primers, and linked to pMD19-T; the linking product was transformed into
15 *Escherichia coli* DH5 α ; the plasmid was extracted and identified; and the correctly identified pMD19-T-F plasmid was used for the next experiment.

[0061] 3. With the PCR technique, the target fragments A and B were amplified by using the pBrLosata plasmid as a template (primers for the fragment A:
5' CACGTG AAAGCGCCAGAGAAGATTCCCGGGA 3'; P2: 5'
20 TTTGGGGCCCATCTTGCACCTGGAGGGCGCCAACCGG 3'; P3: 5'
TCCAGGTGCAAGATGGGCCCCAAACCCCCACCGGAA 3'. B fragment
primers: P6: 5' CCTCATCTGTGT TCATGTTTTTGTGGTGGCTCTCATC 3'; P7: 5'
ACAAAAACATGAACACAGATGAGGAACGAAGGTTTCC 3'; and P8: 5'
GGCCTGAGAGGCCACGCGTCGCCGCGGGCCGGTT 3'). The target fragment F
25 was amplified by using the pMD19-T-F plasmid as a template, and the fragments A, F
and B were extracted by gel. Then, the fragment A-F-B of interest was amplified by

the overlap PCR method using the purified fragments A, F and B as templates, and linked to a pMD19-T vector; the linking product was transformed into Escherichia coli DH5 α ; plasmids were extracted and identified; and the correctly identified plasmids were named as pMD19-T-A-F-B, which carry two digestion sites PmlI and SfiI.

[0062] 4. The plasmids pMD19-T-A-F-B from step 3 were digested using restriction enzymes PmlI and SfiI, and the cleaved product was extracted by gel.

[0063] 5. The pBrLosata plasmid was digested using the restriction enzymes PmlI and SfiI, and the vector was extracted by gel.

[0064] 6. The digested product from step 4 and the vector from step 5 were linked to obtain a recombinant chimeric plasmid pBrLosata-F. PCR and double digestion identification were performed on the recombinant chimeric plasmid; the correctly identified plasmid samples were sub-packaged and sent to Shanghai Sangon for sequencing. The sequencing results were aligned using sequence analysis software DNAMAN; and the plasmid with the sequencing result consistent with a sequence of interest was named as pBrLosata-F. The nucleotide sequence of the recombinant chimeric plasmid pBrLosata-F was as set forth in SEQ ID NO:1 of the sequence listing (the nucleotide sequence at positions 7274-8935 from the 5'-terminus in SEQ ID NO: 1 was the nucleotide sequence of the F gene).

[0065] Other recombinant chimeric plasmids were constructed in the same way: pBrLosata-HN (HN gene sequence, GenBank: AAS67136.1) pBrLosata-P (P gene sequence in GenBank: AAS67133.1), pBrLosata-M (M gene sequence in GenBank: AAS67134.1).

[0066] II. Determination of optimal insertion position for exogenous gene

[0067] 1. Restriction Enzyme cutting sites were respectively introduced to the NP/P, P/M, M/F, and F/HN sites of the pBrLosata-F plasmid using a molecular

biology method. Recombinant plasmids pBrLosata-F-NP/P (AscI, SfiI), pBrLosata-F-P/M (SacII, PmeI), pBrLosata-F-M/F (HpaI, MluI), and pBrLosata-F-F/HN (HpaI, MluI) were obtained.

[0068] 2. RFP gene fragments carrying different restriction enzyme cutting sites were amplified by PCR using specific primers for a red fluorescent protein RFP gene (red fluorescent protein RFP gene sequence in GenBank: MG719763.1), and linked to a pMD19-T vector; the linking product was transformed into Escherichia coli DH5 α ; and the plasmid was extracted and identified as carrying different restriction enzyme cutting sites.

[0069] 3. The plasmid from step 2 was digested using a restriction enzyme, and the cleaved product was extracted by gel.

[0070] 4. The recombinant plasmid from step 1 was digested using a restriction enzyme, and the vector was extracted by gel.

[0071] 5. The digested product from step 3 and the vector from step 4 were linked to obtain recombinant plasmids pBrLosata-F-NP/P-RFP, pBrLosata-F-P/M-RFP, pBrLosata-F-M/F-RFP, and pBrLosata-F-F/HN-RFP.

[0072] 6. BHK-21 cells were co-transfected with the recombinant plasmid from step 5 and the helper plasmid to obtain recombinant virus rLosata-F-NP/P-RFP, rLosata-F-P/M-RFP, rLosata-F-M/F-RFP, and rLosata-F-F/HN-RFP.

[0073] 7. MCF7 cells in the logarithmic growth phase were digested with trypsin and then collected, and seeded into a 6-well plate. The cells were respectively infected with the recombinant chimeric viruses rLosata-F-NP/P-RFP, rLosata-F-P/M-RFP, rLosata-F-M/F-RFP, and rLosata-F-F/HN-RFP at 1 MOI, the parental virus rLosata was used as a control, and the control group was virus-free SPF chicken embryo allantoic fluid. After 24 h, the 6-well plate was taken out, and the average fluorescence intensity of the cells infected with respective virus was detected

by the flow cytometry. The results were shown in FIG. 2, showing the strongest red fluorescence intensity between P and M sites, which indicates the highest RFP expression level between the P and M sites.

[0074] III. Construction of recombinant plasmid inserted with exogenous gene (taking PD1 gene insertion as an example)

[0075] 1. Monocytes were isolated from human peripheral blood cells, and RNA was extracted and reverse-transcribed into cDNA. According to the human PD1 sequence (AY238517.1) that has been published in GenBank, PCR primers P1 and P2 were designed using Primer Premier 5.0 software to clone the complete PD1 gene. Pme I and Sac II digestion sites were designed at both ends of the primers to match the pBrLosata-F vector plasmid.

[0076] 2. The PCR product from step 1 was linked to pMD19-T and transformed into Escherichia coli; plasmids were extracted and identified; and the correctly identified pMD19-T-PD1 plasmids were used for the next experiment.

[0077] 3. The pMD19-PD1 plasmids from step 2 were digested using restriction enzymes Pme I and Sac II, and the cleaved product was extracted by gel.

[0078] 4. The pBrLosata-F plasmids were digested using restriction enzymes Pme I and Sac II, and the vector was extracted by gel.

[0079] 5. The cleaved product from step 3 was linked to the vector from step 4 to obtain a recombinant chimeric plasmid pBrLosata(F)-PD1, with the PD1 gene inserted between the P and M genes of the plasmid. PCR as well as Pme I and Sac II double digestion identification were performed on the recombinant chimeric plasmid; the correctly identified plasmid samples were sub-packaged and sent to Shanghai Sangon for sequencing. The sequencing results were aligned using sequence analysis software DNAMAN; and the sequenced result was consistent with a sequence of interest. The PD1 nucleotide sequence of the recombinant chimeric

plasmid pBrLosata(F)-PD1 was as set forth in SEQ ID NO. 6 in the sequence listing.

[0080] Other recombinant chimeric plasmids inserted with exogenous genes were constructed using the same method. The constructed recombinant chimeric plasmids were specifically as follows: pBrLosata(F)-DR5 (a DR5 sequence as set forth in SEQ ID NO: 2), pBrLosata(F)-TRAIL (a TRAIL sequence as set forth in SEQ ID NO: 3), pBrLosata(F)-hIL2 (a hIL2 sequence as set forth in SEQ ID NO: 4), pBrLosata(F)-P53 (a P53 sequence as set forth in SEQ ID NO:5), pBrLosata(F)-CD (a CD sequence as set forth in SEQ ID NO: 7), pBrLosata(F)-mIL12 (a mIL12 sequence as set forth in SEQ ID NO: 8), pBrLosata(F)-DR5-TRAIL (i.e., a DR5-TRAIL combination as the exogenous gene), pBrLosata(F)-mIL12-hIL2 (i.e., a mIL12-hIL2 combination as the exogenous gene), pBrLosata(F)-P53-hIL2 (i.e., a P53-hIL2 combination as the exogenous gene), and pBrLosata(F)-PD1-hIL2 (i.e., a PD1-hIL2 combination as the exogenous gene).

[0081] IV. Preparation of recombinant chimeric virus

[0082] 1. BHK-21 cells were co-transfected respectively with the plasmid pBrLosata, the recombinant chimeric plasmids pBrLosata-HN, pBrLosata-F, pBrLosata-P, pBrLosata-M, pBrLosata(F)-DR5, pBrLosata(F)-TRAIL, pBrLosata(F)-hIL2, pBrLosata(F)-P53, pBrLosata(F)-PD1, pBrLosata(F)-CD, pBrLosata(F)-mIL12, pBrLosata(F)-DR5-TRAIL, pBrLosata(F)-mIL12-hIL2, pBrLosata(F)-P53-hIL2 and pBrLosata(F)-PD1-hIL2, together with the helper plasmids pBL-NP, pBL-P and pBL-L (about 1×10^6 cells transfected with 2 μ g of recombinant chimeric plasmids, 1 μ g of pBL-N plasmids, 0.5 μ g of pBL-P plasmids and 0.25 μ g of pBL-L plasmids). The transfected cells were placed in a 5% CO₂ environment at 37°C for static culture for 72 h.

[0083] 2. The transfected cells obtained in step 1 were repeatedly frozen and thawed three times, centrifuged to collect the cell supernatant, then seeded into the allantoic cavities of 9-11-day-old SPF chicken embryos. The chicken embryo

allantoic cavities were cultured for 72 h in an environment at 37°C, and the chicken embryo allantoic fluid was collected for HA detection.

[0084] 3. The HA-positive chicken embryo allantoic liquid obtained in step 2 was passaged, seeded into the allantoic cavities of fresh 9-11-day-old SPF chicken embryos, and cultured for 72 h in an environment at 37°C. The chicken embryo allantoic liquid was collected for HA detection. The HA-positive chicken embryo allantoic liquid was passaged for 10 generations, and the proliferation stability of the recombinant viruses was detected.

[0085] 4. The chicken embryo allantoic liquid obtained from step 3 was taken for mass reproduction of the viruses, then seeded into the allantoic cavities of new 9-11-day-old SPF chicken embryos, and cultured for 72 h in an environment at 37°C. The chicken embryo allantoic liquid was collected for HA detection. The allantoic liquid with the HA titer greater than 2^9 was selected, mixed and sub-packaged for later use.

[0086] 5. The allantoic liquid was collected from each group for Western Blot to detect the expression of each exogenous gene. The results showed that, compared with the rLosata group, the recombinant chimeric viruses expressing the exogenous gene was capable of stably expressing the exogenous gene.

[0087] In the following description, unless otherwise specified, the recombinant chimeric viruses, the chimeric viruses and the recombinant viruses refer to the recombinant chimeric viruses prepared by the above methods. rLosata-HN, rLosata-F, rLosata-P, rLosata-M, rLosata(F)-DR5, rLosata(F)-TRAIL, rLosata(F)-hIL2, rLosata(F)-P53, rLosata(F)-PD1, rLosata(F)-CD, rLosata(F)-mIL12, rLosata(F)-DR5-TRAIL, rLosata(F)-mIL12-hIL2, rLosata(F)-P53-hIL2 and rLosata(F)-PD1-hIL2 respectively refer to the recombinant chimeric viruses prepared with the above methods by using the recombinant chimeric plasmids pBrLosata-HN, pBrLosata-F, pBrLosata-NP, pBrLosata-M, pBrLosata(F)-DR5, pBrLosata(F)-TRAIL,

pBrLosata(F)-hIL2, pBrLosata(F)-P53, pBrLosata(F)-PD1, pBrLosata(F)-CD, pBrLosata(F)-mIL12, pBrLosata(F)-DR5-TRAIL, pBrLosata(F)-mIL12-hIL2, pBrLosata(F)-P53-hIL2 and pBrLosata(F)-PD1-hIL2.

[0088] In the following description, unless otherwise specified, the parental viruses refer to the Newcastle disease viruses rLosata and Anhinga.

[0089] Example 3: Determination of virulence and pathogenicity of recombinant chimeric viruses

[0090] I. Determination of EID₅₀

[0091] The rescued recombinant chimeric viruses or parental viruses were serially diluted 10 times with sterilized PBS respectively. Chicken embryos were taken out from an incubator at 37°C. Six 9-11-day-old SPF chicken embryos were seeded with the viruses at each dilution (100 µL for each), and incubated in the incubator at 37°C for 4-6 days. Each chicken embryo needed to be detected by HA assay. The number of embryos infected at each dilution was recorded. The EID₅₀ of each of the recombinant chimeric viruses or parental viruses was calculated according to a Reed and Muench method.

[0092] II. Determination of TCID₅₀

[0093] 1. DF-1 cells were seeded into a 96-well microplate by using a DMEM medium containing 10% FBS and 1% antibiotics, and held in a 5% CO₂ incubator at 37°C overnight.

[0094] 2. Before the recombinant chimeric viruses and the parental viruses were seeded, the original cell culture medium added in step 1 was discarded, and 180 µL of fresh DMEM culture medium containing 10% allantoic fluid and 1% antibiotics.

[0095] 3. 20 μ L of the recombinant chimeric viruses or parental viruses was seeded into the top row of cell wells; the mixture was gently pipetted up and mixed; and 20 μ L of the mixture was pipetted to the lower cell wells for 10-fold serial dilution. Three replicates were set up for each virus.

5 **[0096]** 4. In the 5% CO₂ cell incubator at 37°C, the recombinant chimeric viruses or parental viruses were seeded and incubated for 1 h; then, the culture medium added in step 3 was discarded, and the residue was washed with PBS; and then, 200 μ L of fresh DMEM culture medium containing 10% allantoic fluid and 1% antibiotics was added.

10 **[0097]** 5. The culture continued in a 5% CO₂ cell incubator at 37°C. After 72 h, the wells with cytopathy were observed under an optical inverted microscope, the number of wells with cytopathy was recorded, and the titer of the respective virus was calculated according to the Reed and Muench method.

[0098] III. Determination of MDT

15 **[0099]** The recombinant chimeric viruses or parental viruses were serially diluted 10 times with sterilized PBS respectively. The viruses subjected to doubling dilution were seeded to six 10-day-old SPF chicken embryos (100 μ L for each) via allantoic cavities, and were continuously cultured for 7 days in the incubator at 37°C. The death time and death number of the chicken embryos seeded at each dilution were
20 checked and recorded every 12 hours. Finally, the death times of all chicken embryos seeded at the highest dilution ratio of the viruses are averaged as the MDT of the viruses in discussion.

[00100] IV. Determination of ICPI

25 **[00101]** According to the OIE standard, the recombinant chimeric viruses or parental viruses were first subjected to serial 10-fold dilution with sterilized PBS, and then intracerebrally seeded to ten 1-day-old SPF chicks (50 μ L for each).

Observations were continuously conducted for 10 days to record the daily morbidity and mortality of the chicks, and the intracerebral pathogenicity index of the viruses was calculated according to the Reed and Muench method.

[00102] The results of the measured virulence and pathogenicity of the recombinant chimeric viruses in Example 3 were shown in Table 1. The ICPI value of the parental virus strain Anhinga was 1.47; the ICPI values of rLosata-HN, rLosata-P and rLosata-M were significantly lower than that of Anhinga, and were 0.05, 0.11, and 0.17 respectively; and the ICPI value of rLosata-F was 1.59, which is also lower than that of Anhinga. The results showed that, compared with the parental virus strain Anhinga, the HN, P, M and F replacements could reduce the pathogenicity of Anhinga in chickens. rLosata-F as a recombinant virus showed higher controllability and safety than Anhinga.

Table 1 Comparison of virus titer, virulence, and pathogenicity

Virus	HA	TCID ₅₀	EID ₅₀	MDT	ICPI
rLosata	2 ⁹	2.09×10 ⁷	6.67×10 ⁹	>120 h	0.00
Anhinga	2 ⁷	3.24×10 ⁷	4.27×10 ⁸	82 h	1.47
rLosata-HN	2 ⁷	1.13×10 ⁷	1×10 ⁹	>120 h	0.05
rLosata-P	2 ⁹	1.1×10 ⁸	3.56×10 ⁹	>120 h	0.11
rLosata-F	2 ⁹	1.62×10 ⁸	6.67×10 ⁹	96h	1.17
rLosata- M	2 ⁹	1.16×10 ⁸	2.24×10 ⁹	>120 h	0.17
rLosata(F)-DR5	2 ⁹	3.67×10 ⁷	3.78×10 ⁹	94h	1.11
rLosata(F)-TRAIL	2 ⁹	4.6×10 ⁷	2.29×10 ⁹	90h	1.23
rLosata(F)-hIL2	2 ¹⁰	1.71×10 ⁸	6.67×10 ⁹	96h	1.07
rLosata(F)-P53	2 ⁹	3.92×10 ⁷	3.37×10 ⁹	96h	1.20
rLosata(F)-PD1	2 ¹⁰	1.92×10 ⁸	4.92×10 ⁹	94h	1.12
rLosata(F)-CD	2 ⁹	4.11×10 ⁷	2.12×10 ⁹	98h	1.07
rLosata(F)-mIL12	2 ⁹	3.16×10 ⁷	3.52×10 ⁹	98h	1.06
rLosata(F)-DR5-TRAIL	2 ⁹	3.16×10 ⁷	3.61×10 ⁹	92h	1.20
rLosata(F)-mIL12-hIL2	2 ⁹	1.61×10 ⁸	4.67×10 ⁹	96h	1.17
rLosata(F)-P53-hIL2	2 ⁹	4.11×10 ⁷	3.92×10 ⁹	94h	1.21
rLosata(F)-PD1-hIL2	2 ¹⁰	1.58×10 ⁸	5×10 ⁹	98h	1.11

[00103] Example 4: Killing effect of recombinant chimeric virus against tumour cells as detected in cell fusion experiment

[00104] The tumour cells refer to liver cancer cells HepG2, kidney cancer cells Caki-1, non-small cell lung cancer cells A549, melanoma cells SK-MEL-5, or neuroblastoma cells LN229.

[00105] I. Infection of tumour cells with recombinant chimeric viruses

[00106] Tumour cells in the logarithmic growth phase were digested with trypsin and then collected, and seeded into a 6-well plate. The cells were infected with the recombinant chimeric viruses rLosata-HN, rLosata-F, rLosata-P, and rLosata-M at 1 MOI respectively, the parental virus rLosata was used as a control, and a control group was a virus-free SPF chicken embryo allantoic fluid. After 24 h, the 6-well plate was taken out, and observed under the inverted fluorescent microscope for a cell fusion effect. The results could be found in FIG. 3A to FIG. 3E.

[00107] The results showed that, compared with the parental viruses, the recombinant chimeric viruses rLosata-HN, rLosata-P, and rLosata-M produced more syncytia than rLosata, but without significant difference; and the chimeric virus rLosata-F produced more syncytia than rLosata, with an extremely significant difference.

[00108] Example 5: Effect of recombinant chimeric virus on tumour cells

[00109] The tumour cells refer to liver cancer cells HepG2, kidney cancer cells Caki-1, non-small cell lung cancer cells A549, melanoma cells SK-MEL-5, or neuroblastoma cells LN229.

[00110] I. Detection of inhibitory effect of recombinant chimeric virus on tumour cells by MTT method

[00111] Tumour cells in the logarithmic growth phase were digested by trypsin, and then, prepared into a cell suspension of 2×10^4 cells/mL by using the DMEM or RPMI-1640 culture medium containing 10% calf serum. The cell suspension was seeded in a 96-well plate (200 μ l per well), placed in a 5% CO₂ environment at 37°C for static culture for 24 h; the culture supernatant was discarded; and the residue was washed with a PBS buffer and then grouped. 100 μ L of chimeric viruses at 0.01 MOI, 0.1 MOI, 1 MOI, and 10 MOI were added to each group of

experimental wells, respectively; 100 µL of rLosata at 0.01 MOI, 0.1 MOI, 1 MOI, and 10 MOI was added to the control group, respectively; and 100 µL of DMEM was added to negative control wells. After 1 h of virus infection, the virus solution was discarded, 200 µL of PBS was added to each well for washing once; and a cell maintenance medium containing 5% serum was added for culture. After culturing for 24 h and 48 h respectively, 20 µL of MTT solution (5 mg/mL) was added to each well and incubated for 4 h; the culture solution was discarded; 150 µL of DMSO was added to each well; and after oscillating for 10 min, the OD value at 490 nm was measured with a microplate reader, and the cell growth inhibition rate was calculated.

[00112] Inhibition rate = (OD value of negative control treated well — OD value of experimental treated well) / OD value of negative control treated well × 100%.

[00113] The inhibition rate against HepG-2 cells could be found in FIG. 4; the inhibition rate against Caki-1 cells could be found in FIG. 5; the inhibition rate against A549 cells could be found in FIG. 6; the inhibition rate against SK-MEL-5 cells could be found in FIG. 7; and the inhibition rate against LN229 cells could be found in FIG. 8.

[00114] The results showed that both the parental virus rLosata and the chimerical viruses rLosata-HN, rLosata-F, rLosata-P, and rLosata-M showed an inhibitory effect on the above cells; the inhibitory effect of the chimeric virus Losata-F is significantly higher than that of the parental virus rLosata; the inhibitory effects of other chimeric viruses rLosata-HN, rLosata-NP, and rLosata-M are higher than that of the parental virus rLosata, without significant difference; and the killing effects of the recombinant viruses on the tumour cells were positively correlated with time and dose.

[00115] II. Killing effect of recombinant chimeric virus against liver cancer cells as detected by Annexin V/PI method

[00116] HepG2 tumour cells in the logarithmic growth phase were collected and prepared into a cell suspension of $1-10 \times 10^4$ cells/mL (containing 0.001% trypsin). The cell suspension was mixed well and added to a 6-well plate, and after the cells grew to 60-80%, group experiments were carried out.

5 [00117] HepG2 cells added with the virus-free SPF chicken embryo allantoic fluid were taken as a null cell control group (control); HepG2 cells added with 1 MOI rLosata were taken as a control group; and HepG2 cells added with 1 MOI recombinant chimeric viruses were taken as experiment groups.

10 [00118] After 12 hours of infection, the cells ($0.5-1 \times 10^6$ cells) were digested with 0.25% trypsin, and washed twice with PBS; 500 uL of binding buffer was pipetted with a pipette to gently suspend the cells; 10 μ L of FITC-labeled Annexin-V was added and mixed well; 5 μ L of PI was then added and mixed well; immediately after 5-15 minutes of reaction in the dark, quantitative detection was carried out by flow cytometry; and at the same time, the HepG2 cells without AnnexinV-FITC and
15 PI added were set up as a negative control.

[00119] The results could be found in FIG. 9 and showed that both the parental viruses and the recombinant chimeric viruses could induce the apoptosis of tumour cells; the effect of the virus rLosata-F was significantly stronger than that of the virus rLosata; and the effects of other recombinant chimeric viruses were not
20 significantly different from that of the virus rLosata.

[00120] Example 6: Therapeutic effect of recombinant chimeric virus on tumours and virus safety detection

[00121] I. Therapeutic effect of recombinant chimeric virus on tumours

[00122] 1. Establishment of Balb/c mice H22 liver cancer animal model

25 [00123] Kunming mice of 6 weeks old were used for experiments. H22 mice

liver cancer cells were seeded into the abdominal cavities of Humming mice, and after 7 days, the ascites occurred, and the mice were sacrificed by neck breakage. The ascites containing H22 cells was extracted under a sterile condition; a proper amount of PBS was added to formulate a cancer cell suspension; and the cells were counted and measured in viability, with the viable cell rate up to 95%. The cell density was adjusted to 10^6 cells/mL for later use. Subcutaneous injection was performed on each Balb/c mouse at the right groin at a dose of 0.2 mL, approximately containing 2×10^5 tumour cells. After 8-12 days, when a solid tumour with a diameter of 5-8 mm was formed, the modeling was successful, and the subsequent experiments could be carried out. The mice with the tumour diameter of 5-8 mm were selected, from which individuals with greatly varied forms and sizes were removed, and the remaining mice were taken as model mice.

[00124] 2. Therapeutic effect of recombinant chimeric virus on tumours

[00125] The model mice were randomly divided into six groups, with 15 mice in each group. They were treated as follows:

[00126] an rLosata-HN group: 0.2 mL of rLosata-HN virus solution (containing 10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 14-day treatment;

[00127] an rLosata-F group: 0.2 mL of rLosata-F virus solution (containing 10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 14-day treatment;

[00128] an rLosata-P group: 0.2 mL of rLosata-P virus solution (containing 10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 14-day treatment;

[00129] an rLosata-M group: 0.2 mL of rLosata-M virus solution (containing 10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model

mice every day for 14-day treatment;

[00130] an rLosata group: 0.2 mL of rLosata virus solution (containing 10^7 pfu viruses) was injected into the tumours of the model mice every day for 14-day treatment;

5 **[00131]** an allantoic fluid group (Model): 0.2 mL of allantoic fluid was injected to the tumour of each model mice every day, and treated for 14 days.

[00132] The tumour volume was measured every other day. After the treatment was completed, the mice were sacrificed, the tumours were removed and measured in terms of volume and weight (the results were shown in FIG. 10 and FIG. 10 11). The survival conditions of the remaining mice were observed after the treatment was completed, and the control group included normal mice without any treatment (FIG. 12). The results showed that, compared with the allantoic fluid group, both the parental viruses and the chimeric viruses showed significant inhibitory effects on the tumours; the anti-tumour effects of rLosata-P and rLosata-M were higher than that of 15 the rLosata-HN group, without significant difference; and the inhibitory effect of rLosata-F is significantly higher than those of the above three types of chimeric viruses. Compared with the allantoic fluid group, both the parental viruses and the chimeric viruses could significantly improve the survival rate of the mice; and compared with the rLosata group, only rLosata-F could significantly improve the 20 survival rate of the mice.

[00133] 3. Observation of pathological sections of tumours

[00134] To observe the tumour tissue cell morphology of NDV chimeric viruses and the control group after treatment, tumour tissues were acquired from each group of mice after treatment, and were prepared into tumour tissue paraffin sections 25 following the conventional method. The morphological characteristics of tumour tissues in each treatment group were observed under a microscope, and then compared

and analysed.

[00135] The results showed that after treatment, the tumour tissues from the model group were dense in structure with intact cell morphology and vigorous growth; and the tumour tissues from the rLosata virus control group undergone slight necrosis; the rLosata-HN, rLosata-P, and rLosata-M groups exhibited incomplete cell structure, accompanied with lymphocytes infiltration to a certain extent; and the rLosata-F group exhibited loose tumour tissues and incomplete cell structure, accompanied with massive lymphocytes infiltration. (See FIG. 13)

[00136] II. Safety detection of recombinant chimeric viruses

[00137] Acute toxicity test

[00138] Health Kunming mice of 4-6 weeks old were selected, 20 mice in total including half female and half male, and the mice were divided into two groups, 10 mice in each group. The mice in the control group were fed normally. Each mouse in the experiment groups was intraperitoneally injected with 1×10^4 pfu of rLosata-F, and was observed for 48 hours after injection. If the mice under test experienced respiratory depression, unsteady limbs, paralysis symptoms, convulsions, fur trembles and other adverse reactions, and death, these mice were determined to be positive.

[00139] Subacute toxicity test

[00140] Health Kunming mice of 4-6 weeks old were selected, 20 mice in total including half female and half male, and the mice were divided into two groups, 10 mice in each group. Each mouse in the experiment groups was intraperitoneally injected with 1×10^4 pfu of rLosata-F, and the mice in the control group were fed normally. The responses of the mice were continuously recorded within 4 weeks, and the observations focused on aspects such as water intake, food intake, fur colour and body weight. If everything is normal without any adverse reaction or death, these mice were determined to be negative.

[00141] The results showed that the recombinant chimeric viruses had no adverse effect on the normal growth of mice, and were safe and reliable.

[00142] Example 7: Effects of recombinant chimeric viruses expressing exogenous genes on tumour cells

5 **[00143]** The tumour cells included liver cancer cells HCCLM3, melanoma cells SK-MEL2, lung cancer cells A549, pancreatic cancer cells ASPC-1, thyroid cancer cells FTC133, kidney cancer cells 786-O, neuroblastoma cells U87-MG, myosarcoma cells HT1080, esophageal cancer cells KYSE-150, uterine cancer cells Hela, breast cancer cells MCF7, and colorectal cancer cells HCT116.

10 **[00144]** I. Detection of inhibitory effect of recombinant chimeric virus on tumour cells by MTT method

15 **[00145]** Tumour cells in the logarithmic growth phase were digested by trypsin, and then prepared into a cell suspension at 2×10^4 cells/mL by using a DMEM, F12 or RPMI-1640 culture medium containing 10% calf serum. The cell suspension was seeded in a 96-well plate (200 μ L per well), placed in a 5% CO₂ environment at 37°C for static culture for 24 h; the culture supernatant was discarded; and the residue was washed with a PBS buffer and then grouped. 100 μ L of 0.1 MOI chimeric viruses expressing exogenous genes were added to each group of experimental wells; 0.1 MOI rLosata -F was added to the control group; and 100 μ L of DMEM was added to the negative control wells. After 1 h of virus infection, the virus solution was discarded, 200 μ L of PBS was added to each well for washing once; and a cell maintenance medium containing 5% serum was added for culture. After culturing for 24 h, 20 μ L of MTT solution (5 mg/mL) was added to each well and incubated for 4 h; the culture solution was discarded; 150 μ L of DMSO was added to each well; and after oscillating for 10 min, the OD value at 490 nm was measured with a microplate reader, and the cell growth inhibition rate was calculated (the results were shown in Table 2).

[00146] Inhibition rate = (OD value of negative control treated well — OD value of experimental treated well) / OD value of negative control treated well * 100%.

5

Table 2 Inhibitory effects of recombinant viruses expressing different exogenous genes on different tumour cells (inhibition rate %)

	rLosata-F	rLosata(F)-DR5	rLosata(F)-TRAIL	rLosata(F)-hIL2	rLosata(F)-P53	rLosata(F)-PD1	rLosata(F)-CD	rLosata(F)-mIL12	rLosata(F)-DR5-TRAIL	rLosata(F)-mIL12-hIL2	rLosata(F)-P53-hIL2	rLosata(F)-PD1-hIL2
HCCLM3	27.39	32.55	27.50	42.13	35.83	32.43	30.17	33.43	55.56	57.73	50.95	55.04
SK-MEL2	21.39	32.55	32.49	49.83	31.95	30.44	31.67	38.43	48.06	60.73	56.95	60.04
U87-MG	19.39	24.69	25.88	41.83	27.96	40.87	37.25	28.44	33.18	42.83	46.95	43.04
786-O	15.89	19.56	17.83	26.84	22.95	23.43	31.25	23.46	38.18	42.84	36.97	38.56
FTC133	18.89	21.55	20.34	26.84	35.45	28.43	21.25	22.93	33.78	38.23	34.45	33.04
HT1080	13.47	18.33	19.62	25.98	23.46	25.87	32.25	32.93	29.12	31.88	39.95	35.64
Hela	11.96	28.09	17.84	30.22	10.45	12.86	9.63	15.67	33.10	32.83	24.95	29.94
ASPC-1	11.22	19.84	17.11	21.99	29.66	15.49	16.62	19.79	26.81	25.77	32.54	24.87
A549	15.41	17.26	18.98	16.14	26.22	22.39	20.16	25.9	24.69	28.12	29.95	30.66
KYSE-150	11.28	15.04	17.56	24.65	17.45	14.31	15.09	21.93	25.18	30.56	26.03	21.87
MCF7	9.8	17.63	16.56	25.66	14.45	29.74	15.09	14.43	21.89	26.31	25.53	33.28
HCT116	12.25	15.58	19.52	13.16	16.08	26.57	20.02	18.93	22.59	27.09	29.12	33.96

[00147] The results showed that rLosata(F)-DR5, rLosata(F)-TRAIL, rLosata(F)-hIL2, rLosata(F)-P53, rLosata(F)-PD1, rLosata(F)-CD, rLosata(F)-mIL12, rLosata(F)-DR5-TRAIL, rLosata(F)-mIL12-hIL2, rLosata(F)-P53-hIL2 and rLosata(F)-PD1-hIL2a all showed inhibitory effects on the above cells, and showed higher inhibition rate against HCCLM3, SK-MEL2, FTC133, 786-O, U87-MG, and HT1080 than against A549, ASPC-1, KYSE-150, Hela, MCF7, and HCT116. Also, different virus strains did not exhibit completely identical cytotoxicity against A549, ASPC-1, KYSE-150, Hela, MCF7, and HCT116. Among these 12 types of tumour cells, rLosata(F)-DR5, rLosata(F)-TRAIL, and rLosata(F)-DR5-TRAIL showed higher inhibition rate against Hela cells; rLosata(F)-P53 and rLosata(F)-P53-hIL2 showed higher inhibition rate against A549 and ASPC-1 cells; rLosata(F)-hIL2, rLosata(F)-mIL12 and rLosata(F)-mIL12-hIL2 showed higher inhibition rate against A549, KYSE-150, and Hela cells; rLosata(F)-CD showed higher inhibition rate against A549 cells; and rLosata(F)-PD1 and rLosata(F)-PD1-hIL2 showed higher inhibition rate against A549, MCF7 and HCT116 cells.

[00148] Example 8: Therapeutic effect of recombinant chimeric virus expressing exogenous gene on tumours

[00149] 1. Balb/c 4T1 breast tumour-bearing mice were established according to the method described in Example 6.

5 **[00150]** 2. Therapeutic effect of recombinant chimeric virus on tumours

[00151] The model mice were randomly divided into 13 groups, with 10 mice in each group. These groups were treated as follows respectively:

10 **[00152]** an rLosata(F)-DR5 group: 0.1 mL of rLosata(F)-DR5 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00153] an rLosata(F)-TRAIL group: 0.1 mL of rLosata(F)-TRAIL virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

15 **[00154]** an rLosata(F)-hIL2 group: 0.1 mL of rLosata(F)-hIL2 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00155] an rLosata(F)-P53 group: 0.1 mL of rLosata(F)-P53 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

20 **[00156]** an rLosata(F)-PD1 group: 0.1 mL of rLosata(F)-PD1 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00157] an rLosata(F)-CD group: 0.1 mL of rLosata(F)-CD virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours

of the model mice every day for 21-day treatment;

[00158] an rLosata(F)-mIL12 group: 0.1 mL of rLosata(F)-mIL12 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

5 **[00159]** an rLosata(F)-DR5-TRAIL group: 0.1 mL of rLosata(F)-DR5-TRAIL virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

10 **[00160]** an rLosata(F)-mIL12-hIL2 group: 0.1 mL of rLosata(F)-mIL12-hIL2 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

[00161] an rLosata(F)-P53-hIL2 group: 0.1 mL of rLosata(F)-P53-hIL2 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

15 **[00162]** an rLosata(F)-PD1-hIL2 group: 0.1 mL of rLosata(F)-PD1-hIL2 virus solution (containing 5×10^7 pfu viruses) prepared in Example 1 was injected into the tumours of the model mice every day for 21-day treatment;

20 **[00163]** an rLosata-F group: 0.1 mL of rLosata virus solution (containing 5×10^7 pfu viruses) was injected into the tumours of the model mice every day for 21-day treatment;

[00164] an allantoic fluid group (Model): 0.1 mL of allantoic fluid was injected to the tumour of each model mice every day, and treated for 21 days.

[00165] The tumour volume was measured every other day. After the treatment was completed, the mice were sacrificed, the tumours were removed and

measured in weight (the results as shown in Table 3). The results showed that compared with the allantoic fluid group, rLosata-F and the recombinant chimeric viruses expressing the exogenous genes exhibited significant inhibitory effects on the tumours; the anti-tumour effects of rLosata(F)-DR5, rLosata(F)-TRAIL and rLosata(F)-CD are higher than that of the rLosata-F group, without significant difference; the anti-tumour effects of rLosata(F)-P53 and rLosata(F)-mIL12 are significantly higher than that of the rLosata-F treatment group; and the anti-tumour effects of rLosata(F)-hIL2 and rLosata(F)-PD1 showed extremely significant differences from the rLosata-F group. Compared with a single-gene treatment group, a dual-gene treatment group showed a further enhanced inhibitory effect against tumours. The rLosata(F)-mIL12-hIL2 and rLosata(F)-PD1-hIL2 groups exhibited the best effect, and the tumours in several mice almost regressed after the treatment was completed.

Table 3 Average volume and tumour weight of recombinant chimeric viruses expressing exogenous genes after the completion of treatment

	Average volume before treatment	Average volume after the completion of treatment	Average tumour weight after the completion of treatment
Model	108.66mm ³	1886.53mm ³	1.33 g
rLosata-F	123.30mm ³	1152.25mm ³	1.01 g
rLosata(F)-DR5	146.88mm ³	846.69mm ³	0.86 g
rLosata(F)-TRAIL	116.88mm ³	759.84mm ³	0.79 g
rLosata(F)-hIL2	143.59mm ³	516.74mm ³	0.51 g
rLosata(F)-P53	142.58mm ³	607.42mm ³	0.62 g
rLosata(F)-PD1	133.55mm ³	508.665mm ³	0.46 g
rLosata(F)-CD	107.38mm ³	992.64mm ³	0.94 g
rLosata(F)-mIL12	127.98mm ³	544.22mm ³	0.67 g
rLosata(F)-DR5-TRAIL	115.26mm ³	462.54mm ³	0.44 g
rLosata(F)-mIL12-hIL2	113.73mm ³	309.82mm ³	0.25 g
rLosata(F)-P53-hIL2	127.29mm ³	401.58mm ³	0.38 g
rLosata(F)-PD1-hIL2	130.43mm ³	289.28mm ³	0.18 g

[00166] Example 9: Safety detection of recombinant chimeric viruses expressing exogenous genes on tumours

[00167] Healthy SPF Balb/c mice of 6 weeks old were selected and grouped, 10 mice in each group. The mice in the control group were fed normally. Each mouse in the experiment groups was intraperitoneally injected with 5×10^8 pfu (10 times the

therapeutic dose) recombinant chimeric virus (rLosata(F)-DR5, rLosata(F)-TRAIL, rLosata(F)-hIL2, rLosata(F)-P53, rLosata(F)-PD1, rLosata(F)-CD, rLosata(F)-mIL12, rLosata(F)-DR5-TRAIL, rLosata(F)-mIL12-hIL2, rLosata(F)-P53-hIL2, or rLosata(F)-PD1-hIL2), and then observed for 30 days. As a result, the mice with obvious adverse reactions such as listlessness occurred, ruffled fur and death were determined as positive. After the observation was completed, the serum of mice in each group was collected to detect AST, ALT and other related indicators.

[00168] The results showed that on the second day after injection, the fur of several mice in the experiment groups ruffled, and their food and water intake were not affected. After one week of continuous injections, the fur of the mice returned to normal; and after continuous observation for one month, none of the mice in each experimental group showed obvious adverse reactions such as listlessness, ruffled fur and death. After the observation was completed, the serum of mice in each group was collected to detect AST, ALT, BUN, CREA and other related indicators by ELISA. The results showed that compared with normal mice, the activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as well as the concentrations of blood urea nitrogen (BUN) and serum creatinine (CREA) in each experiment group slightly increased, without significant difference. The results indicated that the chimeric virus treatment did not induce liver and kidney damage and serious toxic or side effects.

[00169] Finally, it should be noted that the above-mentioned examples are obviously examples given for the purpose of clearly illustrating the present application, and are not intended to limit the embodiments. For a person skilled in the art, other different forms of changes or variations can also be made based on the above description. It is unnecessary or impossible to exhaustively list all the embodiments herein. Furthermore, any obvious changes or variations derived herefrom shall still fall within the protection scope of the present application.

Sequence Listing

<110> JIANGSU KANIONREAL BIOMEDICAL TECHNOLOGY CO., LTD

<120> RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD THEREFOR,
RECOMBINANT PLASMID, AND USE THEREOF

<130> 191071P2

<160> 8

<170> SIPOSequenceListing 1.0

<210> 1

<211> 18391

<212> DNA

<213> Artificial Sequence

<220>

<221> gene

<222> (7274)..(8935)

<400> 1

ctggcgtaat agcgaagagg cccgcaccga tcgcccttcc caacagttgc gtagcctgaa	60
tggcgaatgg gacgcgccct gtagcggcgc attaaagcgc gcgggtgtgg tggttacgcg	120
cagcgtgacc gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc	180
ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg	240
gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc	300
acgtagtggg ccatcgccct gatagacggg ttttcgccct ttgacgttgg agtccacgtt	360
ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggctctattc	420
ttttgattta taagggattt tgccgatttc ggcctatttg ttaaaaaatg agctgattta	480
acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaatttcag gtggcacttt	540
tcgggggaaat gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta	600
tccgctcatg agacaataac cctgataaat gcttcaataa tattgaaaaa ggaagagtat	660
gagtattcaa catttccgtg tcgcccttat tccctttttt gcggcatttt gccttcctgt	720
ttttgctcac ccagaaacgc tgggtgaaagt aaaagatgct gaagatcagt tgggtgcacg	780
agtgggttac atcgaactgg atctcaacag cggtgaagatc cttgagagtt ttcgccccga	840
agaacgtttt ccaatgatga gcacttttaa agttctgcta tgtggcgcgg tattatcccg	900
tattgacgcc gggcaagagc aactcggctg ccgcatacac tattctcaga atgacttggg	960
tgagtactca ccagtcacag aaaagcatct tacggatggc atgacagtaa gagaattatg	1020
cagtgctgcc ataagcatga gtgataacac tgcggccaac ttacttctga caacgatcgg	1080
aggaccgaag gagctaaccg ctttttttca caacatgggg gatcatgtaa ctcgccttga	1140
tcgttgggaa ccggagctga atgaagccat accaaacgac gagcgtgaca ccacgatgcc	1200
tgtagcaatg gcaacaacgt tgcgcaaact attaaactggc gaactactta ctctagcttc	1260
ccggcaacaa ttaatagact ggatggaggc ggataaagtt gcaggaccac ttctgcgctc	1320
ggcccttccg gctggctggt ttattgctga taaatctgga gccggtgagc gtgggtctcg	1380
cggtatcatt gcagcactgg ggccagatgg taagccctcc cgtatcgtag ttatctacac	1440
gacgggcagt caggcaacta tggatgaacg aaatagacag atcgctgaga taggtgcctc	1500
actgattaag cattggtaac tgtcagacca agtttactca tatatacttt agattgattt	1560
aaaacttcat ttttaattta aaaggatcta ggtgaagatc ctttttgata atctcatgac	1620
caaaatccct taacgtgagt tttcgttcca ctgagcgtca gaccccgtag aaaagatcaa	1680

aggatcttct	tgagatcctt	tttttctgcg	cgtaatctgc	tgcttgcaaa	caaaaaaacc	1740
accgctacca	gcggtgggtt	gtttgccgga	tcaagagcta	ccaactcttt	ttccgaaggt	1800
aactggcttc	agcagagcgc	agataccaaa	tactgtcctt	ctagtgtagc	cgtagttagg	1860
ccaccacttc	aagaactctg	tagcaccgcc	tacatacctc	gctctgctaa	tcctgttacc	1920
agtggctgct	gccagtggcg	ataagtcgtg	tcttaccggg	ttggactcaa	gacgatagtt	1980
accggataag	gcgagcggt	cgggctgaac	gggggggttc	tgcacacagc	ccagcttgga	2040
gcgaacgacc	tacaccgaac	tgagatacct	acagcgtgag	cattgagaaa	gcgccacgct	2100
tcccgaaggg	agaaaggcgg	acaggtatcc	ggtaagcggc	agggctcgga	caggagagcg	2160
cacgagggag	cttccagggg	ggaacgcctg	gtatctttat	agtcctgtcg	ggtttcgcca	2220
cctctgactt	gagcgtcgat	ttttgtgatg	ctcgtcaggg	gggccgagcc	tatggaaaaa	2280
cgccagcaac	gcggcctttt	tacggttcct	ggccttttgc	tggccttttg	ctcacatgtt	2340
ctttcctgcg	ttatccccctg	attctgtgga	taaccgtatt	accgcctttg	agtgagctga	2400
taccgctcgc	cgcagccgaa	cgaccgagcg	cagcgagtca	gtgagcgagg	aagcgggaaga	2460
gcgcccataa	cgcaaaccgc	ctctccccgc	gcgttggccg	attcattaat	gcagctggca	2520
cgacaggttt	cccgactgga	aagcgggcag	tgagcgcaac	gcaattaatg	tgagttacct	2580
cactcattag	gcaccccagg	ctttacactt	tatgcttccg	gctcctatgt	tgtgtggaat	2640
tgtgagcgga	taacaatttc	acacaggaaa	cagctatgac	catgattacg	ccaagctcgg	2700
aagcggccgc	taatacgact	cactataggg	accaaacaga	gaatccgtaa	gttacgataa	2760
aaggcgaagg	agcaattgaa	gtcgcacggg	tagaagggtg	gaatctcgag	tgcgagcccg	2820
aagcacaac	tcgagaaaagc	cttctgccaa	catgtcttcc	gtattttgatg	agtacgaaca	2880
gctcctcgcg	gctcagactc	gccccaatgg	agctcatgga	ggggggagaaa	aagggagtag	2940
cttaaaagta	gacgtcccgg	tattcactct	taacagtgat	gaccagaag	atagatggag	3000
ctttgtggta	ttctgcctcc	ggattgctgt	tagcgaagat	gccaacaaac	cactcaggca	3060
aggtgctctc	atatctcttt	tatgctccca	ctcacaggta	atgaggaacc	atgttgccct	3120
tgaggggaaa	cagaatgaag	ccacattggc	cgtgcttgag	attgatggct	ttgccaacgg	3180
cagcccccag	ttcaacaata	ggagtggagt	gtctgaagag	agagcacaga	gatttgcgat	3240
gatagcagga	tctctccctc	gggcatgcag	caacgggaacc	ccgttcgtca	cagccggggc	3300
cgaagatgat	gcaccagaag	acatcaccga	taccctggag	aggatcctct	ctatccaggc	3360
tcaagtatgg	gtcacagtag	caaaagccat	gactgcgtat	gagactgcag	atgagtcgga	3420
aacaaggcga	atcaataagt	atatgcagca	aggcagggtc	caaaagaaat	acatcctcta	3480
ccccgtatgc	aggagcacia	tccaactcac	gatcagacag	tctcttgag	tccgcatctt	3540
tttggttagc	gagctcaaga	gaggccgcaa	cacggcaggt	ggtacctcta	cttattataa	3600
cctggtaggg	gacgtagact	catacatcag	gaataccggg	cttactgcat	tcttcttgac	3660
actcaagtac	ggaatcaaca	ccaagacatc	agcccttgca	cttagtagcc	tctcaggcga	3720
catccagaag	atgaagcagc	tcatgcgttt	gtatcggatg	aaaggagata	atgcgccgta	3780
catgacatta	cttggtgata	gtgaccagat	gagctttgcg	cctgccgagt	atgcacaact	3840
ttactccttt	gccatgggta	tggcatcagt	cctagataaa	ggtactggga	aataccaatt	3900
tgccagggac	tttatgagca	catcattctg	gagacttgga	gtagagtacg	ctcaggctca	3960
gggaagtagc	attaacgagg	atatggctgc	cgagctaaag	ctaaccacag	cagcaaggag	4020
gggcctggca	gctgctgccc	aacgggtctc	cgaggagacc	agcagcatag	acatgcctac	4080
tcaacaagtc	ggagtcctca	ctgggcttag	cgaggggggg	tcccaagctc	tacaaggcgg	4140
atcgaataga	tcgcaagggc	aaccagaagc	cggggatggg	gagacccaat	tcctggatct	4200
gatgagagcg	gtagcaaata	gcatgaggga	ggcgccaaac	tctgcacagg	gcactcccca	4260
atcggggcct	cccccaactc	ctgggccatc	ccaagataac	gacaccgact	gggggtattg	4320
atggacaaaa	cccagcctgc	ttccacaaaa	acatcccaat	gccctcacc	gtagtcgacc	4380
cctcgatttg	cggctctata	tgaccacacc	ctcaaacaaa	catccccctc	tttctcctct	4440
ccccctgctg	tacaactccg	cacgccctag	ataccacagg	cacaatgcgg	ctcactaaca	4500
atcaaaaacag	agccgaggga	attagaaaaa	agtacgggta	gaagagggat	attcagagat	4560
cagggcaagt	ctcccgagtc	tctgctctct	cctctacctg	atagaccagg	acaacatgg	4620
ccacctttac	agatgcagag	atcgacgagc	tatttgagac	aagtggaaact	gtcattgaca	4680
acataattac	agcccagggt	aaaccagcag	agactgttgg	aaggagtgc	atcccacaag	4740
gcaagaccaa	ggtgctgagc	gcagcatggg	agaagcatgg	gagcatccag	ccaccggcca	4800

gtcaagacaa	ccccgatcga	caggacagat	ctgacaaaca	accatccaca	cccgagcaaa	4860
cgacccccgca	tgacagcccg	ccggccacat	ccgccgacca	gccccccacc	caggccacag	4920
acgaagccgt	cgacacacag	ctcaggaccg	gagcaagcaa	ctctctgctg	ttgatgcttg	4980
acaagctcag	caataaatcg	tccaatgcta	aaaagggccc	atggtcgagc	ccccaaagagg	5040
ggaatcacca	acgtccgact	caacagcagg	ggagtcaacc	cagtcgcgga	aacagtcagg	5100
aaagaccgca	gaaccaagtc	aaggccgccc	ctggaaacca	gggcacagac	gtgaacacag	5160
catatcatgg	acaatgggag	gagtcacaac	tatcagctgg	tgcaaccctt	catgctctcc	5220
gatcaaggca	gagccaagac	aatacccttg	tatctgcgga	tcatgtccag	ccacctgtag	5280
actttgtgca	agcgatgatg	tctatgatgg	aggcgatatc	acagagagta	agtaagggttg	5340
actatcagct	agatcttgct	ttgaaacaga	catcctccat	ccctatgatg	cggctccgaaa	5400
tccaacagct	gaaaacatct	gttgcaagtca	tggaagccaa	cttggggaatg	atgaagattc	5460
tggtatcccg	ttgtgccaac	atttcatctc	tgagtgatct	acgggcagtt	gcccgatctc	5520
acccgggtttt	agtttcaggc	cctgggagacc	cctctcccta	tgtgacacaa	ggaggcgaaa	5580
tggcacttaa	taaactttcg	caaccagtg	cacatccatc	tgaattgatt	aaacccgcca	5640
ctgcatgcgg	gcctgatata	ggagtggaaa	aggacactgt	ccgtgcattg	atcatgtcac	5700
gccaatgca	cccaggttct	tcagccaagc	tcctaagcaa	gttagatgca	gccgggtcga	5760
tcgaggaaat	caggaaaatc	aagcgcttg	ctctaaatgg	ctaattacta	ctgccacacg	5820
tagcgggtcc	ctgtccactc	ggcatcacac	ggaatctgca	ccgagttccc	ccccgcagac	5880
ccaaggtcca	acttccaag	cggcaatcct	ctctcgcttc	ctcagcccca	ctgaatgatc	5940
gcgtaaccgt	aattaatcta	gctacattta	agattaagaa	aaaatacggg	tagaattgga	6000
gtgccccaat	tgtgccaaga	tggactcatc	taggacaatt	gggctgtact	ttgattctgc	6060
ccattcttct	agcaacctgt	tagcatttcc	gatcgctcta	caagacacag	gagatgggaa	6120
gaagcaaadc	gccccgcaat	ataggatcca	gcgccttgac	ttgtggactg	atagtaagga	6180
ggactcagta	ttcatcacca	cctatggatt	catctttcaa	gttggggaatg	aagaagccac	6240
tgtcggcatg	atcgatgata	aacccaagcg	cgagttactt	tccgctgcga	tgctctgcct	6300
aggaagcgtc	ccaaataaccg	gagaccttat	tgagctggca	agggcctgtc	tcactatgat	6360
agtcacatgc	aagaagagtg	caactaatac	tgagagaatg	gttttctcag	tagtgcaggc	6420
accccaagtg	ctgcaaagct	gtagggttgt	ggcaaacaaa	tactcatcag	tgaatgcagt	6480
caagcacgtg	aaagcgccag	agaagattcc	cgggagtgga	accctagaat	acaagggtgaa	6540
ctttgtctcc	ttgactgtgg	taccgaagaa	ggatgtctac	aagatcccag	ctgcagtatt	6600
gaaggtttct	ggctcgagtc	tgtacaatct	tgcgctcaat	gtcactatta	atgtggagggt	6660
agacccgagg	agtcctttgg	ttaaatctct	gtctaagtct	gacagcggat	actatgctaa	6720
cctcttcttg	catattggac	ttatgaccac	cgtagatagg	aaggggaaga	aagtgcattt	6780
tgacaagctg	gaaaagaaaa	taaggagcct	tgatctatct	gtcgggctca	gtgatgtgct	6840
cgggccttcc	gtgttggtaa	aagcaagagg	tgacaggact	aagcttttgg	cacctttctt	6900
ctctagcagt	gggacagcct	gctatcccat	agcaaatgct	tctcctcagg	tggccaagat	6960
actctggagt	caaaccgcgt	gcctgcggag	cgttaaaatc	attatccaag	caggtagcca	7020
acgcgctgtc	gcagtgaccg	ccgaccacga	ggttacctct	actaagctgg	agaaggggca	7080
cacccttgcc	aaatacaatc	cttttaagaa	ataagctgcg	tctctgagat	tgcgctccgc	7140
ccactcacc	agatcatcat	gacacaaaaa	actaatctgt	cttgattatt	tacagttagt	7200
ttacctgtct	atcaagttag	aaaaaacacg	ggtagaagat	tctggatccc	ggttggcgcc	7260
ctccagggtg	aagatgggcc	ccaaaccccc	caccggaacc	ccagcgcttc	tggtgctgat	7320
cgcccgacc	gcgctggcgt	tgggctgtgt	ctgtccggcg	ggctctcttg	acggcagacc	7380
tcttgagct	gcagggttg	tggtaacgag	agataaagca	gtcaatatat	acacttcatc	7440
tcaaacgggg	tcaatcatag	tcaagttact	cccaaataatg	cccaaggaca	aggaggcgtg	7500
cgcaaaagcc	ccattagagg	crtacaatag	aacactgacc	actttactca	ctcctcttgg	7560
ygactccatc	cgsaggatac	aagggtctgc	aactacatct	agagggaagga	gacagaaacg	7620
ttttgtaggt	gctatcattg	gcagtatagc	tcttgggggt	gcgacagctg	cacaagtaac	7680
agcagctgca	gctctgatac	aagccaacca	gaacgctgcc	aacatcctcc	ggcttaagga	7740
gagcattgct	gcaaccaatg	aagctgtgca	cgaggctact	gacggattat	cacaactagc	7800
gatggcgatt	gggaagatgc	agcagtttgt	taatgaccag	tttaataata	cggcgcgaga	7860
attggactgc	atcaaaaatta	cacaacaggt	tggtgtcgaa	ctcaatttgt	atctaactga	7920

actgactaca	gtattcgggc	cacaaatcac	ttcccctgct	ttaactcagc	taactatcca	7980
ggcactttat	aatttagctg	gtggcaatat	gaattactta	ttgactaagt	taggtgtagg	8040
gaacaatcaa	cttagctcat	taattagtag	tggcctgata	actggcaacc	ccattttata	8100
tgactcacag	acccaactct	taggcataca	gataaatgta	ccctcagtcg	ggagcctaaa	8160
taatatgcgt	gccacctact	tggagacctt	atccgtaagc	acaaccaggg	ggttcgcctc	8220
agcacttgct	ccgaaaagttg	tgacgcaagt	tggttctgtg	atagaagaac	ttgacacctc	8280
atattgtata	gaatctaata	tggatttata	ttgtacaagg	atagtacat	tccccatgtc	8340
tcccggcatt	tattcctgtc	tgagcggtaa	tacgtcagct	tgtatgtatt	caaagactga	8400
gggtgcactc	actacaccat	acatagctct	caagggctca	gttattgcta	attgcaagat	8460
gattacatgt	agatgtgcag	acccccagg	tatcatatcg	caaaattacg	gagaagctgt	8520
gtccctaata	gataaacatt	catgtaatgt	cttatcccta	gacggaataa	ccctgaggct	8580
cagtggggaa	tttgatgcga	cctatcaaaa	gaacatctta	atactagatt	cccaggtcat	8640
cgtagacagg	aatctcgata	tatcaactga	acttgggaat	gtcaacaact	cgataagcag	8700
tgctctggac	aaattagcgg	aaagtaacag	caagttaaac	aaagtcaatg	tcaacctaac	8760
tagcacatct	gctctcatta	cttatattgt	tctagctgtc	atatctcttg	ttttcggcgt	8820
aattagcctg	attctagcgt	gctgcttgat	gtataaacia	aaagcacaac	aaaagacctt	8880
actatggctt	gggaacaata	ccctcgatca	gatgagagcc	accacaaaaa	catgaacaca	8940
gatgaggaac	gaaggtttcc	ctaatagtaa	tttgtgtgaa	agttctggta	gtctgtcagt	9000
taagaaaaaa	tacgggtaga	aggttaaccg	gcccgcggcg	acgctgggcc	tgagaggcct	9060
tcagagaggt	aagaaaaaac	taccggttgt	agatgaccaa	aggacgatat	acgggtagaa	9120
cggtaagaga	ggccgccccct	caattgagag	ccaggcttca	caacctccgt	tctaccgctt	9180
caccgacaac	agtcctcaat	catggaccgc	gccgttagcc	aagttgcgtt	agagaatgat	9240
gaaagagagg	caaaaaatac	atggcgcttg	atattccgga	ttgcaatctt	attcttaaca	9300
gtagtacact	tggctatatc	tgtagcctcc	cttttatata	gcatgggggc	tagcacacct	9360
agcgatcttg	taggcatacc	gactaggatt	tccagggcag	aagaaaagat	tacatctaca	9420
cttggttcca	atcaagatgt	agtagatagg	atatataagc	aagtggccct	tgagtctccg	9480
ttggcattgt	taaaatactga	gaccacaatt	atgaacgcaa	taacatctct	ctcttatcag	9540
attaatggag	ctgcaaaacia	cagtgggttg	ggggcaccta	tccatgaccc	agattatata	9600
ggggggatag	gcaaagaact	cattgtagat	gatgctagtg	atgtcacatc	attctatccc	9660
tctgcatttc	aagaacatct	gaattttatc	ccggcgcccta	ctacaggatc	aggttgcaat	9720
cgaataaccct	catttgacat	gagtgtacc	cattactgct	acaccataa	tgtaatatgt	9780
tctggatgca	gagatcactc	acattcatat	cagtatttag	cacttggtgt	gctccggaca	9840
tctgcaacag	ggagggtatt	cttttctact	ctgcgttcca	tcaacctgga	cgacacccaa	9900
aatcggaagt	cttgcaagtgt	gagtgcact	cccctgggtt	gtgatatgct	gtgctcgaaa	9960
gtcacggaga	cagaggaaga	agattataac	tcagctgtcc	ctacgcggat	ggtacatggg	10020
aggttagggg	tcgacggcca	gtaccacgaa	aaggacctag	atgtcacac	attattcggg	10080
gactgggtgg	ccaactaccc	aggagtaggg	ggtggatctt	ttattgacag	ccgcgtatgg	10140
ttctcagctc	acggagggtt	aaaacccaat	tcacccagtg	acactgtaca	ggaaggga	10200
tatgtgatata	acaagcgata	caatgacaca	tgcccagatg	agcaagacta	ccagattcga	10260
atggccaagt	cttcgtataa	gcctggacgg	tttggtggga	aacgcataca	gcaggctatc	10320
ttatctatca	agggtgtcaac	atccttaggc	gaagaccggg	tactgactgt	accgccaac	10380
acagtcacac	tcatgggggc	cgaaggcaga	attctcacag	tagggacatc	tcatttcttg	10440
tatcaacgag	ggtcatcata	cttctctccc	gcgttattat	atcctatgac	agtcagcaac	10500
aaaacagcca	ctcttcatag	tccttatata	ttcaatgcct	tcactcggcc	aggtagtatc	10560
ccttgccagg	cttcagcaag	atgccccaac	tcgtgtgtta	ctggagtcta	tacagatcca	10620
tatccccata	tcttctatag	aaaccacacc	ttgcgagggg	tattcgggac	aatgcttgat	10680
ggtgtacaag	caagacttaa	ccctgcgtct	gcagtattcg	atagcacatc	ccgcagtcgc	10740
attactcgag	tgagttcaag	cagtacaaa	gcagcataca	caacatcaac	ttgttttaaa	10800
gtgggtcaaga	ctaataagac	ctattgtctc	agcattgtctg	aaatatctaa	tactctcttc	10860
ggagaattca	gaatcgctcc	gttactagtt	gagatcctca	aagatgacgg	ggtttagagaa	10920
gccagggtctg	gctagttgag	tcaattataa	aggagttgga	aagatggcat	tgtatcacct	10980
atcttctgcg	acatcaagaa	tcaaaccgaa	tgccggcgcg	tgctcgaatt	ccatgttgcc	11040

agttgaccac	aatcagccag	tgctcatgcg	atcagattaa	gccttgtcaa	tagtctcttg	11100
attaagaaaa	aatgtaagt	gcaatgagat	acaaggcaaa	acagctcatg	gtaaataata	11160
cgggtaggac	atggcgagct	ccggtcctga	aagggcagag	catcagatta	tcctaccaga	11220
gtcacacctg	tcttcaccat	tggtcaagca	caaactactc	tattactgga	aattaactgg	11280
gctaccgctt	cctgatgaat	gtgacttcga	ccacctcatt	ctcagccgac	aatggaaaaa	11340
aatacttgaa	tcggcctctc	ctgatactga	gagaatgata	aaactcggaa	gggcagtaca	11400
ccaaactctt	aaccacaatt	ccagaataac	cggagtgtct	caccccaggt	gtttagaaga	11460
actggctaata	attgagggtcc	cagattcaac	caacaaattt	cggaagattg	agaagaagat	11520
ccaaattcac	aacacgagat	atggagaact	gttcacaagg	ctgtgtacgc	atatagagaa	11580
gaaactgctg	gggtcatctt	ggtctaacaa	tgtcccccg	tcagaggagt	tcagcagcat	11640
tcgtacggat	ccggcattct	ggtttcactc	aaaatggtcc	acagccaagt	ttgcatggct	11700
ccatataaaa	cagatccaga	ggcatctgat	gggtggcagct	aggacaaggt	ctgcggccaa	11760
caaattgggtg	atgctaacc	ataaggtagg	ccaagtcttt	gtcactcctg	aacttgtctg	11820
tgtgacgcat	acgaatgaga	acaagttcac	atgtcttacc	caggaacttg	tattgatgta	11880
tgcagatatg	atggagggca	gagatatggt	caacataata	tcaaccacgg	cggtgcatct	11940
cagaagctta	tcagagaaaa	ttgatgacat	tttgcggtta	atagacgctc	tggcaaaaga	12000
cttgggtaata	caagtctacg	atgttgatc	actaatggag	ggatttgcat	acggagctgt	12060
ccagctactc	gagccgtcag	gtacatttgc	aggagatttc	ttcgcatcca	acctgcagga	12120
gcttaaagac	attctaattg	gcctcctccc	caatgatata	gcagaatccg	tgactcatgc	12180
aatcgctact	gtatttcttg	gtttagaaca	gaatcaagca	gctgagatgt	tgtgtctgtt	12240
gcgtctgtgg	ggtcacccac	tgcttgagtc	ccgtattgca	gcaaaggcag	tcaggagcca	12300
aatgtgcgca	ccgaaaatgg	tagactttga	tatgatcctt	caggtactgt	ctttcttcaa	12360
gggaacaatc	atcaacgggt	acagaaagaa	gaatgcaggt	gtgtggccgc	gagtcaaagt	12420
ggatacaata	tatgggaagg	tcattgggca	actacatgca	gattcagcag	agatttcaca	12480
cgatatcatg	ttgagagagt	ataagagttt	atctgcactt	gaatttgagc	catgtataga	12540
atatgaccct	gtcaccaacc	tgagcatgtt	cctaaaagac	aaggcaatcg	cacaccccaa	12600
cgataattgg	cttgccctcg	ttaggcggaa	ccttctctcc	gaagaccaga	agaaacatgt	12660
aaaagaagca	acttcgacta	atcgccctct	gatagagttt	ttagagtcaa	atgattttga	12720
tccatataaa	gagatggaat	atctgacgac	ccttgagtac	ccttagagatg	acaatgtggc	12780
agtatcatat	tcgctcaagg	agaaggaagt	gaaagttaat	ggacggatct	tcgctaagct	12840
gacaaagaag	ttaaggaaact	gtcaggtgat	ggcgggaagg	atcctagccg	atcagattgc	12900
acctttcttt	cagggaatg	gagtcattca	ggatagcata	tccttgacca	agagtatgct	12960
agcgatgagt	caactgtctt	ttaacagcaa	taagaaacgt	atcactgact	gtaaagaaag	13020
agtatcttca	aaccgcaatc	atgatccgaa	aagcaagaac	cgtcggagag	ttgcaacctt	13080
cataacaact	gacctgcaaa	agtactgtct	taattggaga	tatcagacaa	tcaaattgtt	13140
cgctcatgcc	atcaatcagt	tgatgggcct	acctcacttc	ttcgaatgga	ttcacctaag	13200
actgatggac	actacgatgt	tcgtaggaga	ccctttcaat	cctccaagtg	accctactga	13260
ctgtgacctc	tcaagagtcc	ctaataatga	catatatatt	gtcagtcca	gagggggtat	13320
cgaaggatta	tgccagaagc	tatggacaat	gatctcaatt	gctgcaatcc	aacttgctgc	13380
agctagatcg	cattgtcgtg	ttgcctgtat	ggtacagggt	gataatcaag	taatagcagt	13440
aacgagagag	gtaagatcag	acgactctcc	ggagatgggtg	ttgacacagt	tgcatcaagc	13500
cagtataaat	ttcttcaagg	aattaattca	tgtcaatcat	ttgattggcc	ataatttgaa	13560
ggatcgtgaa	accatcaggt	cagacacatt	cttcatatac	agcaaacgaa	tcttcaaaga	13620
tggagcaatc	ctcagtcaag	tcctcaaaaa	ttcatctaaa	ttagtgctag	tgtcaggtga	13680
tctcagtga	aacaccgtaa	tgtcctgtgc	caacattgcc	tctactgtag	cacggctatg	13740
cgagaacggg	cttcccaaag	acttctgtta	ctattttaa	tatatataatga	gttgtgtgca	13800
gacatacttt	gactctgagt	tctccatcac	caacaattcg	caccccgatc	ttaatcagtc	13860
gtggattgag	gacatctctt	ttgtgcactc	atatgttctg	actcctgccc	aattaggggg	13920
actgagtaac	cttcaatact	caaggctcta	cactagaaat	atcggtgacc	cgggggactac	13980
tgctttttgca	gagatcaagc	gactagaagc	agtgaggatta	ctgagtccta	acattatgac	14040
taatatctta	actaggccgc	ctgggaatgg	agattgggcc	agtctgtgca	acgaccata	14100
ctcttttcaat	tttgagactg	ttgcaagccc	aaatatgttt	cttaagaaac	atacgcaaag	14160

agtcctat	ttt	gaaacttg	tt	caaatcc	ctt	attgtct	gga	gtgcacac	ag	aggataat	ga	14220
ggcagaag	ag	aaggcatt	gg	ctgaatt	ctt	gcttaat	caa	gaggtgat	tc	atccccgc	gt	14280
tgcgcatg	cc	atcatgg	agg	caagctc	tgt	aggtagg	aga	aagcaaatt	c	aagggc	ttgt	14340
tgacaca	aaca	aacaccg	taa	ttaagatt	gc	gcttact	agg	aggccatt	ag	gcatcaag	ag	14400
gctgatg	cgg	atagtca	att	ttctag	cat	gcatgca	atg	ctgtttag	ag	acgatgt	ttt	14460
ttcctcc	cagt	agatcca	aacc	acccctt	agt	ctcttcta	aat	atgtgtt	ctc	tgacact	ggc	14520
agactat	gca	cggaata	gaa	gctggtc	acc	tttgacg	gga	ggcagga	aaa	tactggg	tgt	14580
atcta	atcct	gatacg	atag	aactcgt	aga	gggtgag	att	cttagtg	taa	gcggagg	gtg	14640
tacaaga	tgt	gacagcg	gag	atgaaca	att	tacttggt	tc	catcttcc	aa	gcaatat	aga	14700
attgacc	gat	gacacc	agca	agaatc	ctcc	gatgagg	gta	ccatatct	c	ggtcaa	agac	14760
acaggag	agg	agagctg	cct	cacttgca	aaa	aatagct	cat	atgtcgcc	ac	atgtaa	aggc	14820
tgcccta	aagg	gcatcat	cgc	tgttgat	ctg	ggcttat	ggg	gataatg	aag	taaattg	gac	14880
tgctgct	ctt	acgattg	caa	aatctcg	gtg	taatgtaa	ac	ttagagt	atc	ttcggtt	tact	14940
gtcccc	ttta	cccacgg	ctg	ggaatct	tca	acatagac	t	gatgatg	gta	taactc	agat	15000
gacattc	cacc	cctgcat	ctc	tctacag	ggg	gtcacct	tac	attcacat	at	ccaatg	attc	15060
tcaaagg	ctg	ttcactg	aag	aaggagt	caa	agagggg	aat	gtggttt	acc	aacagat	cat	15120
gctcttg	ggg	ttatctc	ttaa	tcgaatc	gat	ctttcca	ata	acaaca	acca	ggacata	tga	15180
tgagatc	aca	ctgcac	ctac	atagtaa	att	tagttg	ctgt	atcagaga	aag	cacctgt	tgc	15240
ggttc	ctttc	gagctac	tgt	gggtgg	tacc	ggaactg	agg	acagtga	cct	caaata	agtt	15300
tatgtat	gat	cctagcc	ctg	tatcgg	agg	agacttt	gcg	agacttg	act	tagctac	ttt	15360
caagagt	tat	gagctta	atc	tggagt	cata	tcccac	gata	gagcta	atga	acattct	tttc	15420
aatatcc	cagc	gggaagt	tga	ttggcc	cagtc	tgtgg	tttct	tatgat	gaag	atacct	ccat	15480
aaagaat	gac	gccataa	tag	tgtatg	acaa	taccg	aaat	tggatc	agtg	aagctc	agaa	15540
ttcagat	gtg	gtccgc	ctat	ttgaat	atgc	agcactt	gaa	gtgctc	ctcg	actgtt	ctta	15600
ccaactc	tat	tacctg	agag	taagagg	cct	agacaat	att	gtcttat	ata	tgggtg	attt	15660
atacaag	aat	atgccag	gaa	ttctact	tttc	caacatt	gca	gctaca	aatat	ctcatcc	ggt	15720
cattcatt	c	aggttac	atg	cagtggg	cct	ggtcaac	cat	gacggat	cac	accaact	tgc	15780
agatacg	gat	tttatcg	aaa	tgtctg	caaa	actattag	t	tcttgca	ccc	gacgtgt	gat	15840
ctccggg	ctta	tattcag	gaa	ataagt	atga	tctgctg	t	ccatctg	tct	tagatga	taa	15900
cctgaat	gag	aagatg	cttc	agctgat	atc	ccggttat	gc	tgtctgt	taca	cggtag	ctt	15960
tgctaca	aaca	agagaaa	tcc	cgaata	aag	aggctta	act	gcagaag	aga	aatgtt	caat	16020
actcact	gag	tatttact	gt	cggatg	ctgt	gaaacc	atta	cttagt	ccc	atcaag	t	16080
ctctatc	atg	tctccta	aaca	taattac	att	cccagct	aat	ctgtact	taca	tgtctc	ggaa	16140
gagcctc	aat	ttgatc	agg	aaagg	gagga	caggga	tact	atcctg	gcgt	tgttgt	ccc	16200
ccaagag	cca	ttattag	agt	tccctt	ctgt	gcaagat	att	ggtgct	c	tgaaag	atcc	16260
attcac	ccga	caacctg	cgg	cattttt	gca	agagtt	agat	ttgagt	gctc	cagcaag	gta	16320
tgacgc	attc	acacttag	tc	agattc	atcc	tgaact	caca	tctccaa	atc	cggagga	aga	16380
ctactta	gta	cgatact	tgt	tcagagg	gat	agggact	gca	tcttct	ctt	ggtata	aggc	16440
atctcat	ctc	ctttctg	tac	ccgagg	taag	atgtgca	aga	cacggga	act	ccttata	actt	16500
agctga	agg	agcggag	cca	tcatgag	tct	tctcga	actg	catgtac	cac	atgaa	actat	16560
ctattaca	aat	acgctct	ttt	caatgag	at	gaaccccc	c	caacga	catt	tcgggc	c	16620
cccaact	cag	tttttga	att	cggttg	ttta	taggaat	cta	caggcg	gagg	taacat	gcaa	16680
agatgg	attt	gtccaag	agt	tccgtcc	att	atggag	agaa	aatacag	agg	aaagtga	cct	16740
gacctc	agat	aaagtag	tgg	ggtatatt	ac	atctgc	agtg	ccctac	agat	ctgtat	catt	16800
gctgc	attgt	gacattg	aaa	ttcctcc	agg	gtccaat	caa	agcttact	ag	atcaact	tagc	16860
tatcaat	ttta	tctctg	attg	ccatgc	attc	tgtaagg	gag	ggcggg	gtag	taatcat	caa	16920
agtgtt	gtat	gcaatgg	gat	actact	tttca	tctact	catg	aacttg	ttt	ctccgt	gttc	16980
cacaaa	agga	tatattc	tct	ctaattg	gtta	tgcatgt	cga	ggagata	tgg	agtgtta	cct	17040
ggtattt	gtc	atgggtt	tacc	tgggcg	ggcc	tacattt	gtta	catgagg	tgg	tgaggat	ggc	17100
gaaaact	ctg	gtgcag	cggc	acggtac	gct	tttgtc	t	tcagatg	aga	tcacact	gac	17160
caggtt	attc	acctcac	agc	ggcagc	gtgt	gacagac	atc	ctatcc	agtc	ctttacca	ag	17220
attaata	aaag	tacttg	agga	agaatatt	ga	cactgc	gctg	attgaag	ccg	ggggac	agcc	17280

cgtccgtcca	ttctgtgcgg	agagtctggt	gagcacgcta	gcgaacataa	ctcagataac	17340
ccagatcatc	gctagtcaca	ttgacacagt	tatccggtct	gtgatatata	tggaagctga	17400
gggtgatctc	gctgacacag	tatttctatt	taccccttac	aatctctcta	ctgacgggaa	17460
aaagaggaca	tcacttaaac	agtgcacgag	acagatccta	gaggttacaa	tactaggtct	17520
tagagtcgaa	aatctcaata	aaataggcga	tataatcagc	ctagtgccta	aaggcatgat	17580
ctccatggag	gaccttatcc	cactaaggac	atacttgaag	catagtacct	gccctaaata	17640
tttgaaggct	gtcctaggta	ttaccaaact	caaagaaatg	tttacagaca	cttctgtact	17700
gtacttgact	cgtgctcaac	aaaaattcta	catgaaaact	ataggcaatg	cagtcaaagg	17760
atattacagt	aactgtgact	cttaacgaaa	atcacatatt	aataggctcc	ttttttggcc	17820
aattgtattc	ttgttgattt	aatcatatta	tgttagaaaa	aagttgaacc	ctgactcctt	17880
aggactcgaa	ttcgaactca	aataaatgtc	ttaaaaaaag	gttgcgcaca	attattcttg	17940
agtgtagtct	cgtcattcac	caaatctttg	tttggtttgg	tggccggcat	gggtcccagcc	18000
tcctcgctgg	cgccggctgg	gcaacattcc	gaggggaccg	tcccctcggg	aatggcgaat	18060
gggacgcggc	cgatccggct	gctaacaaaag	cccgaaggga	agctgagttg	gctgctgcca	18120
ccgctgagca	ataactagca	taacccttgg	gggcctctaa	acgggtcttg	aggggttttt	18180
tgctgaaagg	aggaactata	tccggatcgg	ccgatccggc	tgctaacaaa	gcccgaagg	18240
aagctgagtt	ggctgctgcc	accgctgagc	aataactagc	ataaccctt	ggggcctcta	18300
aacgggtcct	gaggggtttt	ttgctgaaag	gaggaactat	atccggatgg	ccgccaccgg	18360
tgggccttgc	agcacatccc	cccttcgcca	g			18391

<210> 2
 <211> 1236
 <212> DNA
 <213> Homo sapiens

<400> 2						
atggaacaac	ggggacagaa	cgccccggcc	gcttcggggg	cccggaaaag	gcacggccca	60
ggaccacagg	aggcgcgggg	agccaggcct	gggctccggg	tccccaagac	ccttgtgctc	120
gttgctgccg	cggctctgct	gttggtctca	gctgagctctg	ctctgatcac	ccaacaagac	180
ctagctcccc	agcagagagc	ggccccacaa	caaaagaggt	ccagcccctc	agagggattg	240
tgtccacctg	gacaccatat	ctcagaagac	ggtagagatt	gcattctcctg	caaatatgga	300
caggactata	gcactcactg	gaatgacctc	cttttctgct	tgcgctgcac	cagggtgtgat	360
tcagggtgaag	tggagctaag	tccctgcacc	acgaccagaa	acacagtgtg	tcagtgcgaa	420
gaaggcacct	tccgggaaga	agattctcct	gagatgtgcc	ggaagtgccg	cacagggtgt	480
cccagaggga	tgggtcaagg	cgggtgattgt	acaccctgga	gtgacatcga	atgtgtccac	540
aaagaatcag	gcatcatcat	aggagtcaca	gttgcagccg	tagtcttgat	tgtggctgtg	600
tttgtttgca	agtctttact	gtggaagaaa	gtccttcctt	acctgaaagg	catctgctca	660
ggtggtggtg	gggaccctga	gcgtgtggac	agaagctcac	aacgacctgg	ggctgaggac	720
aatgtcctca	atgagatcgt	gagtatcttg	cagcccaccc	aggtccctga	gcaggaaatg	780
gaagtccagg	agccagcaga	gccaacaggt	gtcaacatgt	tgtcccccg	ggagtcagag	840
catctgctgg	aaccggcaga	agctgaaagg	tctcagagga	ggaggctgct	ggttccagca	900
aatgaagggtg	atcccactga	gactctgaga	cagtgccttcg	atgactttgc	agacttggtg	960
ccctttgact	cctgggagcc	gctcatgagg	aagttgggcc	tcattggacaa	tgagataaag	1020
gtggctaaaag	ctgaggcagc	gggccacagg	gacaccttgt	acacgatgct	gataaagtgg	1080
gtcaacaaaa	ccgggcgaga	tgcctctgtc	cacaccctgc	tggatgcctt	ggagacgctg	1140
ggagagagac	ttgccaagca	gaagattgag	gaccacttgt	tgagctctgg	aaagttcatg	1200
tatctagaag	gtaatgcaga	ctctgccatg	tcctaa			1236

<210> 3
 <211> 624
 <212> DNA
 <213> Homo sapiens

<400> 3
atggagacag acacactcct gctatgggta ctgctgctct gggttccagg atccactggt 60
acctctgagg aaaccatttc tacagttcaa gaaaagcaac aaaatatttc tcccctagt 120
agagaaagag gtcctcagag agtagcagct cacataactg ggaccagagg aagaagcaac 180
acattgtctt ctccaaactc caagaatgaa aaggctctgg gccgcaaat aaactcctgg 240
gaatcatcaa ggagtgggca ttcattcctg agcaacttgc acttgaggaa tggatgaactg 300
gtcatccatg aaaaagggtt ttactacatc tattcccaaa catactttcg atttcaggag 360
gaaataaaag aaaacacaaa gaacgacaaa caaatggtcc aatatattta caaatacaca 420
agttatcctg accctatatt gttgatgaaa agtgctagaa atagtgtgtg gtctaaagat 480
gcagaatatg gactctattc catctatcaa gggggaatat ttgagcttaa ggaaaatgac 540
agaatttttg tttctgtaac aaatgagcac ttgatagaca tggaccatga agccagtttt 600
ttcggggcct ttttagttgg ctaa 624

<210> 4
<211> 462
<212> DNA
<213> Homo sapiens

<400> 4
atgtacagga tgcaactcct gtcttgcatc gcactaagtc ttgcacttgt cacaacacagt 60
gcacctactt caagttctac aaagaaaaca cagctacaac tggagcattt actgctggat 120
ttacagatga ttttgaatgg aattaataat tacaagaatc ccaaactcac caggatgctc 180
acatttaagt tttacatgcc caagaaggcc acagaactga aacatcttca gtgtctagaa 240
gaagaactca aacctctgga ggaagtgtca aatttagctc aaagcaaaaa ctttacttta 300
agaccagggg acttaatcag caatatcaac gtaatagttc tggaaactaaa gggatctgaa 360
acaacattca tgtgtgaata tgctgatgag acagcaacca ttgtagaatt tctgaacaga 420
tggattacct tttgtcaaag catcatctca acactgactt aa 462

<210> 5
<211> 1182
<212> DNA
<213> Homo sapiens

<400> 5
atggaggagc cgcagtcaga tcctagcgtc gagccccctc tgagtcagga aacattttca 60
gacctatgga aactacttcc tgaaaacaac gttctgtccc ccttgccgtc ccaagcaatg 120
gatgatattga tgctgtcccc ggacgatatt gaacaatggt tcaactgaaga cccagggtcca 180
gatgaagctc ccagaatgcc agaggctgct cccccgtgg cccctgcacc agcagctcct 240
acaccggcgg cccctgcacc agccccctcc tggccccgtg catcttctgt cccttcccag 300
aaaacctacc agggcagcta cggtttccgt ctgggcttct tgcatcttg gacagccaag 360
tctgtgactt gcacgtactc ccctgccctc aacaagatgt tttgccaaact ggccaagacc 420
tgccctgtgc agctgtgggt tgattccaca cccccgccg gcacccgcgt ccgcgccatg 480
gccatctaca agcagtcaca gcacatgacg gaggttgtga ggcgctgccc ccacatgag 540
cgctgctcag atagcgatgg tctggcccc cctcagcatc ttatccgagt ggaaggaaat 600
ttgcgtgtgg agtatttggg tgacagaaac acttttcgac atagtgtggg ggtgccctat 660
gagccgcctg aggttggctc tgactgtacc accatccact acaactacat gtgtaacagt 720
tcctgcatgg gcggcatgaa ccggaggccc atcctcacca tcatcacact ggaagactcc 780
agtggtaatc tactgggacg gaacagcttt gaggtgctg tttgtgcctg tcctggggaga 840
gaccggcgca cagaggaaga gaatctccgc aagaaagggg agcctcacca cgagctgccc 900
ccaggagca ctaagcgagc actgccaac aacaccagct cctctcccca gccaaagaag 960
aaaccactgg atggagaata tttcaccctt cagatccgtg ggcgtgagcg cttcgagatg 1020

ttccgagagc	tgaatgaggc	cttggaactc	aaggatgccc	aggctgggaa	ggagccaggg	1080
gggagcaggg	ctcactccag	ccacctgaag	tccaaaaagg	gtcagtctac	ctcccgccat	1140
aaaaaactca	tgttcaagac	agaagggcct	gactcagact	ga		1182

<210> 6
 <211> 504
 <212> DNA
 <213> Homo sapiens

<400> 6						
atggagacag	acacactcct	gctatgggta	ctgctgctct	gggttccagg	atccactggg	60
ccaggatggg	tcttagactc	cccagacagg	ccctggaacc	ccccacctt	ctcccagcc	120
ctgctcgtgg	tgaccgaagg	ggacaacgcc	accttcacct	gcagcttctc	caacacatcg	180
gagagcttcg	tgctaaactg	gtaccgcatg	agccccagca	accagacgga	caagctggcc	240
gccttccccg	aggaccgcag	ccagcccggc	caggactgcc	gcttccgtgt	cacacaactg	300
cccaacgggc	gtgacttcca	catgagcgtg	gtcagggccc	ggcgcaatga	cagcggcacc	360
tacctctgtg	gggcatctc	cctggccccc	aaggcgcaga	tcaaagagag	cctgcgggca	420
gagctcaggg	tgacagagag	aagggcagaa	gtgcccacag	cccaccccag	cccctcacc	480
aggccagccg	gccagttcca	atga				504

<210> 7
 <211> 1284
 <212> DNA
 <213> Escherichia coli

<400> 7						
atgtcgaata	acgctttaca	aacaattatt	aacgcccggg	taccaggcga	agaggggctg	60
tggcagattc	atctgcagga	cggaaaaatc	agcgccattg	atgcgcaatc	cggcgtgatg	120
cccataactg	aaaacagcct	ggatgccgaa	caagggttag	ttataccgcc	gtttgtggag	180
ccacatatct	acctggacac	cacgcaaacc	gccggacaac	cgaactggaa	tcagtccggc	240
acgctgtttg	aaggcattga	acgctgggcc	gagcgcaaag	cgttattaac	ccatgacgat	300
gtgaaacaac	gcgcatggca	aacgctgaaa	tggcagattg	ccaacggcat	tcagcatgtg	360
cgtacccatg	tcgatgtttc	ggatgcaacg	ctaactgcgc	tgaagcaat	gctggaagtg	420
aagcaggaag	tcgcgccgtg	gattgatctg	caaatcgctg	ccttccctca	ggaagggatt	480
ttgtcgtatc	ccaacggtga	agcgttgctg	gaagaggcgt	tacgcttagg	ggcagatgta	540
gtggggggcga	ttccgcattt	tgaatttacc	cgtgaatacg	gcgtggagtc	gctgcataaa	600
accttcgccc	tggcgcaaaa	atacgaccgt	ctcatcgacg	ttcactgtga	tgagatcgat	660
gacgagcagt	cgcgctttgt	cgaaacggtt	gctgccctgg	cgcacatga	aggcatgggc	720
gcgcgagtca	ccgccagcca	caccacggca	atgcactcct	ataacggggc	gtatacctca	780
cgcctgttcc	gcttgctgaa	aatgtccggg	attaactttg	tcgccaaccc	gctggtcaat	840
attcatctgc	aaggacgttt	cgatacgtat	ccaaaacgtc	gcggcatcac	gcgcgttaaa	900
gagatgctgg	agtcgggcat	taacgtctgc	tttgggtcacg	atgatgtctt	cgatccgtgg	960
tatccgctgg	gaacggcgaa	tatgctgcaa	gtgctgcata	tggggctgca	tgtttgccag	1020
ttgatgggct	acgggcagat	taacgatggc	ctgaatttaa	tcaccacca	cagcgcaagg	1080
acgttgaatt	tgaggatta	cggcattgcc	gccggaaaca	gcgccaacct	gattatcctg	1140
ccggctgaaa	atgggtttga	tgcgctgcgc	cgtcaggttc	cggtacgtta	ttcggtagct	1200
ggcggcaagg	tgattgccag	cacacaaccg	gcacaaacca	ccgtatatct	ggagcagcca	1260
gaagccatcg	attacaaacg	ttga				1284

<210> 8
 <211> 1623
 <212> DNA

<213> Mus musculus

<400> 8

atgtgtcaat	cacgctacct	cctcttttttg	gccacccttg	ccctcctaaa	ccacctcagt	60
ttggccaggg	tcattccagt	ctctggacct	gccagggtgtc	ttagccagtc	ccgaaacctg	120
ctgaagacca	cagatgacat	ggtgaagacg	gccagagaaa	agctgaaaca	ttattcctgc	180
actgctgaag	acatcgatca	tgaagacatc	acacgggacc	aaaccagcac	attgaagacc	240
tgtttaccac	tggaactaca	caagaacgag	agttgcctgg	ctactagaga	gacttcttcc	300
acaacaagag	ggagctgcct	gccccacag	aagacgtctt	tgatgatgac	cctgtgcctt	360
ggtagcatct	atgaggactt	gaagatgtac	cagacagagt	tccaggccat	caacgcagca	420
cttcagaatc	acaaccatca	gcagatcatt	ctagacaagg	gcattgctgg	ggccatcgat	480
gagctgatgc	agtctctgaa	tcataatggc	gagactctgc	gccagaaacc	tcctgtggga	540
gaagcagacc	cttacagagt	gaaaatgaag	ctctgcatcc	tgcttcacgc	cttcagcacc	600
cgcgtcgtga	ccatcaacag	ggtgatgggc	tatctgagct	ccgccgttcc	tggagtaggg	660
gtacctggag	tgggcggatc	tatgtgggag	ctggagaaag	acgtttatgt	tgtagagggtg	720
gactggactc	ccgatgcccc	tggagaaaca	gtgaacctca	cctgtgacac	gcctgaagaa	780
gatgacatca	cctggacctc	agaccagaga	catggagtca	taggctctgg	aaagaccctg	840
accatcactg	tcaaagagtt	tctagatgct	ggccagtaca	cctgccacaa	aggaggcgag	900
actctgagcc	actcacatct	gctgctccac	aagaaggaaa	atggaatttg	gtccactgaa	960
attttaaaaa	attttcaaaaa	caagactttc	ctgaagtgtg	aagcaccaaa	ttactccgga	1020
cggttcacgt	gctcatggct	ggtgcaaaga	aacatggact	tgaagttcaa	catcaagagc	1080
agtagcagtc	cccccgactc	tcgggcagtg	acatgtggaa	tggcgtctct	gtctgcagag	1140
aaggtcacac	tggaccaaag	ggactatgag	aagtattcag	tgtcctgcca	ggaggatgtc	1200
acctgccccaa	ctgccgagga	gaccctgccc	attgaactgg	cgttgggaagc	acggcagcag	1260
aataaatatg	agaactacag	caccagcttc	ttcatcaggg	acatcatcaa	accagaccgc	1320
cccaagaact	tgcagatgaa	gcctttgaag	aactcacagg	tggaggtcag	ctgggagtac	1380
cctgactcct	ggagcactcc	ccattcctac	ttctccctca	agttctttgt	tcgaatccag	1440
cgcaagaaaag	aaaagatgaa	ggagacagag	gaggggtgta	accagaaagg	tgcgttcctc	1500
gtagagaaga	catctaccga	agtccaatgc	aaaggcggga	atgtctgcgt	gcaagctcag	1560
gacgctatt	acaattcctc	atgcagcaag	tgggcatgtg	ttccctgcag	ggtccgatcc	1620
tag						1623

What is claimed is:

1. A recombinant Newcastle disease virus, being obtained by replacing an F protein of a Newcastle disease virus Losata with an F protein of a Newcastle disease virus mesogenic strain.

2. The recombinant Newcastle disease virus according to claim 1, wherein a coding DNA of an F protein of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1 at positions 7274-8935 from a 5'-terminus.

3 The recombinant Newcastle disease virus according to claim 1, being obtained by replacing an F gene in a genome of the Newcastle disease virus Losata with an F gene of the Newcastle disease virus mesogenic strain, wherein

preferably, a DNA corresponding to the F gene of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1 at the positions 7274-8935 from the 5'-terminus; and

more preferably, a DNA corresponding to a genome of the recombinant Newcastle disease virus is as set forth in SEQ ID NO: 1.

4. The recombinant Newcastle disease virus according to claim 1, wherein a DNA corresponding to a genome of the recombinant Newcastle disease virus further comprises an exogenous gene, which is selected from one or more of a group consisting of DR5, TRAIL, hIL2, P53, PD1, CD, and mIL12;

preferably, the exogenous gene is DR5, TRAIL, hIL2, P53, PD1, CD, or mIL12;

preferably, the exogenous gene is mIL12-hIL2, P53-hIL2, PD1-hIL2, or DR5-TRAIL;

preferably, the DR5 is as set forth in SEQ ID NO: 2, the TRAIL is as set forth in SEQ ID NO: 3, the hIL2 is as set forth in SEQ ID NO: 4, the P53 is as set forth in SEQ ID NO: 5, the PD1 is as set forth in SEQ ID NO: 6, the CD is as set forth

in SEQ ID NO: 7, and the mIL12 is as set forth in SEQ ID NO: 8; and

preferably, the exogenous gene is located between a P gene and an M gene of the recombinant Newcastle disease virus.

5 5. A recombinant plasmid, being obtained by replacing an F gene in a pBrLosata plasmid, wherein the F gene of the recombinant plasmid is as set forth in SEQ ID NO: 1 at positions 7274-8935 from a 5'-terminus.

10 6. The recombinant plasmid according to claim 5, wherein the recombinant plasmid is a DNA molecule plasmid as set forth in SEQ ID NO: 1.

7. The recombinant plasmid according to claim 5, further comprising an exogenous gene, which is selected from one or more of a group consisting of DR5, TRAIL, hIL2, P53, PD1, CD, and mIL12, wherein

15 preferably, the exogenous gene is DR5, TRAIL, hIL2, P53, PD1, CD, or mIL12;

preferably, the exogenous gene is mIL12-hIL2, P53-hIL2, PD1-hIL2, or DR5-TRAIL;

20 preferably, the DR5 is as set forth in SEQ ID NO: 2, the TRAIL is as set forth in SEQ ID NO: 3, the hIL2 is as set forth in SEQ ID NO: 4, the P53 is as set forth in SEQ ID NO: 5, the PD1 is as set forth in SEQ ID NO: 6, the CD is as set forth in SEQ ID NO: 7, and the mIL12 is as set forth in SEQ ID NO: 8; and

preferably, the exogenous gene is located between a P gene and an M gene of a genome of the recombinant Newcastle disease virus.

25 8. A preparation method for a recombinant Newcastle disease virus, comprising transfecting the recombinant plasmid according to any one of claims 5 to 7 to a cell or cell line for culturing to obtain the recombinant Newcastle disease virus.

30 9. The preparation method according to claim 8, wherein

the recombinant plasmid according to any one of claims 5 to 7 and a helper plasmid are co-transfected to cells or cell line for culturing; and
the cell is a mammalian cell.

10. Use of the recombinant Newcastle disease virus according to any one of claims 1 to 4 or the recombinant plasmid according to any one of claims 5 to 7 in preparation of a drug having the following function(s) of (a) and/or (b) and/or (c):

- (a) treating a tumour;
- (b) inhibiting tumour cell proliferation; and
- (c) killing tumour cells.

11. The use according to claim 10, wherein

the tumour is selected from one or more of a group consisting of a liver cancer, a breast cancer, a non-small cell lung cancer, a melanoma, a neuroblastoma, a lung cancer, a pancreatic cancer, a thyroid cancer, a kidney cancer, a glioma, a myosarcoma, an esophageal cancer, a uterine cancer, a breast cancer, and a colorectal cancer; and

the tumour cell is selected from one or more of a group consisting of a liver cancer cell, a breast cancer cell, a non-small cell lung cancer cell, a melanoma cell, a neuroblastoma cell, a lung cancer cell, a pancreatic cancer cell, a thyroid cancer cell, a kidney cancer cell, a glioma cell, a myosarcoma cell, an esophageal cancer cell, a uterine cancer cell, a breast cancer cell, and a colorectal cancer cell.

12. A drug, comprising

the recombinant Newcastle disease virus according to any one of claims 1 to 4, and/or

the recombinant plasmid according to any one of claims 5 to 7, wherein the drug has the following function(s) of (a) and/or (b) and/or (c):

- (a) treating a tumour;
- (b) inhibiting tumour cell proliferation; and

(c) killing tumour cells.